

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>What can National TB Control Programmes in low- and... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1011/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1011" />
    
            <meta name="description" content="Read the original article in full on F1000Research: What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?" />
    
            <meta name="og:title" content="F1000Research Article: What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?.">
            <meta name="og:description" content="Read the latest article version by Anthony D. Harries, Yan Lin, Ajay M.V. Kumar, Srinath Satyanarayana, Kudakwashe C. Takarinda, Riitta A. Dlodlo, Rony Zachariah, Piero L. Olliaro, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="16130">
            <meta name="article-id" content="14821">
            <meta name="dc.title" content="What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?">
            <meta name="dc.description" content="The international community has committed to ending the tuberculosis (TB) epidemic by 2030. This will require multi-sectoral action with a focus on accelerating socio-economic development, developing and implementing new tools, and expanding health insurance coverage. Within this broad framework, National TB Programmes (NTPs) are accountable for delivering diagnostic, treatment, and preventive services. There are large gaps in the delivery of these services, and the aim of this article is to review the crucial activities and interventions that NTPs must implement in order to meet global targets and milestones that will end the TB epidemic. The key deliverables are the following: turn End TB targets and milestones into national measurable indicators to make it easier to track progress; optimize the prompt and accurate diagnosis of all types of TB; provide rapid, complete, and effective treatment to all those diagnosed with TB; implement and monitor effective infection control practices; diagnose and treat drug-resistant TB, associated HIV infection, and diabetes mellitus; design and implement active case finding strategies for high-risk groups and link them to the treatment of latent TB infection; engage with the private-for-profit sector; and empower the Central Unit of the NTP particularly in relation to data-driven supportive supervision, operational research, and sustained financing. The glaring gaps in the delivery of TB services must be remedied, and some of these gaps will require new paradigms and ways of working which include patient-centered and higher-quality services. There must also be fast-track ways of incorporating new diagnostic, treatment, and prevention tools into program activities so as to rapidly reduce TB incidence and mortality and meet the goal of ending TB by 2030.">
            <meta name="dc.subject" content="tuberculosis; world health organization; sustainable development goals; ending the TB epidemic; national tuberculosis programmes; diagnosis; anti-tuberculosis treatment; latent tuberculosis infection ">
            <meta name="dc.creator" content="Harries, Anthony D.">
            <meta name="dc.creator" content="Lin, Yan">
            <meta name="dc.creator" content="Kumar, Ajay M.V.">
            <meta name="dc.creator" content="Satyanarayana, Srinath">
            <meta name="dc.creator" content="Takarinda, Kudakwashe C.">
            <meta name="dc.creator" content="Dlodlo, Riitta A.">
            <meta name="dc.creator" content="Zachariah, Rony">
            <meta name="dc.creator" content="Olliaro, Piero L.">
            <meta name="dc.date" content="2018/07/05">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.14821.1">
            <meta name="dc.source" content="F1000Research 2018 7:1011">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="tuberculosis; world health organization; sustainable development goals; ending the TB epidemic; national tuberculosis programmes; diagnosis; anti-tuberculosis treatment; latent tuberculosis infection ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/07/05">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1011">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.14821.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1011">
            <meta name="citation_title" content="What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?">
            <meta name="citation_abstract" content="The international community has committed to ending the tuberculosis (TB) epidemic by 2030. This will require multi-sectoral action with a focus on accelerating socio-economic development, developing and implementing new tools, and expanding health insurance coverage. Within this broad framework, National TB Programmes (NTPs) are accountable for delivering diagnostic, treatment, and preventive services. There are large gaps in the delivery of these services, and the aim of this article is to review the crucial activities and interventions that NTPs must implement in order to meet global targets and milestones that will end the TB epidemic. The key deliverables are the following: turn End TB targets and milestones into national measurable indicators to make it easier to track progress; optimize the prompt and accurate diagnosis of all types of TB; provide rapid, complete, and effective treatment to all those diagnosed with TB; implement and monitor effective infection control practices; diagnose and treat drug-resistant TB, associated HIV infection, and diabetes mellitus; design and implement active case finding strategies for high-risk groups and link them to the treatment of latent TB infection; engage with the private-for-profit sector; and empower the Central Unit of the NTP particularly in relation to data-driven supportive supervision, operational research, and sustained financing. The glaring gaps in the delivery of TB services must be remedied, and some of these gaps will require new paradigms and ways of working which include patient-centered and higher-quality services. There must also be fast-track ways of incorporating new diagnostic, treatment, and prevention tools into program activities so as to rapidly reduce TB incidence and mortality and meet the goal of ending TB by 2030.">
            <meta name="citation_description" content="The international community has committed to ending the tuberculosis (TB) epidemic by 2030. This will require multi-sectoral action with a focus on accelerating socio-economic development, developing and implementing new tools, and expanding health insurance coverage. Within this broad framework, National TB Programmes (NTPs) are accountable for delivering diagnostic, treatment, and preventive services. There are large gaps in the delivery of these services, and the aim of this article is to review the crucial activities and interventions that NTPs must implement in order to meet global targets and milestones that will end the TB epidemic. The key deliverables are the following: turn End TB targets and milestones into national measurable indicators to make it easier to track progress; optimize the prompt and accurate diagnosis of all types of TB; provide rapid, complete, and effective treatment to all those diagnosed with TB; implement and monitor effective infection control practices; diagnose and treat drug-resistant TB, associated HIV infection, and diabetes mellitus; design and implement active case finding strategies for high-risk groups and link them to the treatment of latent TB infection; engage with the private-for-profit sector; and empower the Central Unit of the NTP particularly in relation to data-driven supportive supervision, operational research, and sustained financing. The glaring gaps in the delivery of TB services must be remedied, and some of these gaps will require new paradigms and ways of working which include patient-centered and higher-quality services. There must also be fast-track ways of incorporating new diagnostic, treatment, and prevention tools into program activities so as to rapidly reduce TB incidence and mortality and meet the goal of ending TB by 2030.">
            <meta name="citation_keywords" content="tuberculosis; world health organization; sustainable development goals; ending the TB epidemic; national tuberculosis programmes; diagnosis; anti-tuberculosis treatment; latent tuberculosis infection ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Anthony D. Harries">
            <meta name="citation_author_institution" content="International Union Against Tuberculosis and Lung Disease, 68 Boulevard Saint Michel, 75006 Paris, France">
            <meta name="citation_author_institution" content="London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK">
            <meta name="citation_author" content="Yan Lin">
            <meta name="citation_author_institution" content="International Union Against Tuberculosis and Lung Disease, 68 Boulevard Saint Michel, 75006 Paris, France">
            <meta name="citation_author_institution" content="International Union Against Tuberculosis and Lung Disease, No. 1 Xindong Road, 100600 Beijing, China">
            <meta name="citation_author" content="Ajay M.V. Kumar">
            <meta name="citation_author_institution" content="International Union Against Tuberculosis and Lung Disease, 68 Boulevard Saint Michel, 75006 Paris, France">
            <meta name="citation_author_institution" content="International Union Against Tuberculosis and Lung Disease, South-East Asia Regional Office, C-6 Qutub Institutional Area, 110016 New Delhi, India">
            <meta name="citation_author" content="Srinath Satyanarayana">
            <meta name="citation_author_institution" content="International Union Against Tuberculosis and Lung Disease, 68 Boulevard Saint Michel, 75006 Paris, France">
            <meta name="citation_author_institution" content="International Union Against Tuberculosis and Lung Disease, South-East Asia Regional Office, C-6 Qutub Institutional Area, 110016 New Delhi, India">
            <meta name="citation_author" content="Kudakwashe C. Takarinda">
            <meta name="citation_author_institution" content="International Union Against Tuberculosis and Lung Disease, 68 Boulevard Saint Michel, 75006 Paris, France">
            <meta name="citation_author_institution" content="AIDS &amp; TB Department, Ministry of Health and Child Care, 2nd Floor, Mukwati Building, Corner Livingstone Avenue and 5th Street, Harare, Zimbabwe">
            <meta name="citation_author" content="Riitta A. Dlodlo">
            <meta name="citation_author_institution" content="International Union Against Tuberculosis and Lung Disease, 68 Boulevard Saint Michel, 75006 Paris, France">
            <meta name="citation_author" content="Rony Zachariah">
            <meta name="citation_author_institution" content="Special Programme for Research and Training in Tropical Disease (TDR), World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland">
            <meta name="citation_author" content="Piero L. Olliaro">
            <meta name="citation_author_institution" content="Special Programme for Research and Training in Tropical Disease (TDR), World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland">
            <meta name="citation_publication_date" content="2018/07/05">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1011">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.14821.1">
            <meta name="citation_firstpage" content="1011">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1011/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1011.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=16130 /> <input type=hidden id=articleId name=articleId value=14821 /> <input type=hidden id=xmlUrl value="/articles/7-1011/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1011-v1.xml"> <input type=hidden id=article_uuid value=0036fea3-c1da-4768-a30f-82c39e0a0b4b /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.14821.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.14821.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1011"
  },
  "headline": "What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?",
  "datePublished": "2018-07-05T21:32:22",
  "dateModified": "2018-07-05T21:32:22",
  "author": [
    {
      "@type": "Person",
      "name": "Anthony D. Harries"
    },    {
      "@type": "Person",
      "name": "Yan Lin"
    },    {
      "@type": "Person",
      "name": "Ajay M.V. Kumar"
    },    {
      "@type": "Person",
      "name": "Srinath Satyanarayana"
    },    {
      "@type": "Person",
      "name": "Kudakwashe C. Takarinda"
    },    {
      "@type": "Person",
      "name": "Riitta A. Dlodlo"
    },    {
      "@type": "Person",
      "name": "Rony Zachariah"
    },    {
      "@type": "Person",
      "name": "Piero L. Olliaro"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The international community has committed to ending the tuberculosis (TB) epidemic by 2030. This will require multi-sectoral action with a focus on accelerating socio-economic development, developing and implementing new tools, and expanding health insurance coverage. Within this broad framework, National TB Programmes (NTPs) are accountable for delivering diagnostic, treatment, and preventive services. There are large gaps in the delivery of these services, and the aim of this article is to review the crucial activities and interventions that NTPs must implement in order to meet global targets and milestones that will end the TB epidemic. The key deliverables are the following: turn End TB targets and milestones into national measurable indicators to make it easier to track progress; optimize the prompt and accurate diagnosis of all types of TB; provide rapid, complete, and effective treatment to all those diagnosed with TB; implement and monitor effective infection control practices; diagnose and treat drug-resistant TB, associated HIV infection, and diabetes mellitus; design and implement active case finding strategies for high-risk groups and link them to the treatment of latent TB infection; engage with the private-for-profit sector; and empower the Central Unit of the NTP particularly in relation to data-driven supportive supervision, operational research, and sustained financing. The glaring gaps in the delivery of TB services must be remedied, and some of these gaps will require new paradigms and ways of working which include patient-centered and higher-quality services. There must also be fast-track ways of incorporating new diagnostic, treatment, and prevention tools into program activities so as to rapidly reduce TB incidence and mortality and meet the goal of ending TB by 2030."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1011",
            "name": "What can National TB Control Programmes in low- and middle-income..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> What can National TB Control Programmes in low- and middle-income... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=16130 data-id=14821 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14821.1" data-recommended="" data-doi="10.12688/f1000research.14821.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1011/v1/pdf?article_uuid=0036fea3-c1da-4768-a30f-82c39e0a0b4b" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-14821-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-14821-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-14821-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Harries AD, Lin Y, Kumar AMV <em>et al.</em> What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030? [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1011 (<a class=new-orange href="https://doi.org/10.12688/f1000research.14821.1" target=_blank>https://doi.org/10.12688/f1000research.14821.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-14821-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=14821 id=track-article-signin-14821 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14821?target=/articles/7-1011">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16130 /> <input name=articleId type=hidden value=14821 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:adharries@theunion.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Anthony D. Harries</span></a><a href="https://orcid.org/0000-0001-6113-9741" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-6113-9741</div><sup>1,2</sup>,&nbsp;</span><span class="">Yan Lin<a href="https://orcid.org/0000-0002-7055-3183" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7055-3183</div><sup>1,3</sup>,&nbsp;</span><span class="">Ajay M.V. Kumar<sup>1,4</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Srinath Satyanarayana<sup>1,4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Kudakwashe C. Takarinda<a href="https://orcid.org/0000-0002-2980-7735" target=_blank id=author-orcid-4><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-4><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2980-7735</div><sup>1,5</sup>,&nbsp;</span><span class="">Riitta A. Dlodlo<sup>1</sup>,&nbsp;</span><span class="">Rony Zachariah<a href="https://orcid.org/0000-0002-2915-9328" target=_blank id=author-orcid-6><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-6><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2915-9328</div><sup>6</sup>,&nbsp;</span><span class="">Piero L. Olliaro<sup>6</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:adharries@theunion.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Anthony D. Harries</span></a><a href="http://orcid.org/0000-0001-6113-9741" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-6113-9741</div><sup>1,2</sup>,&nbsp;</span><span class="">Yan Lin<a href="http://orcid.org/0000-0002-7055-3183" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7055-3183</div><sup>1,3</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Ajay M.V. Kumar<sup>1,4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Srinath Satyanarayana<sup>1,4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Kudakwashe C. Takarinda<a href="http://orcid.org/0000-0002-2980-7735" target=_blank id=mauthor-orcid-4><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-4><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2980-7735</div><sup>1,5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Riitta A. Dlodlo<sup>1</sup>,&nbsp;</span><span class="">Rony Zachariah<a href="http://orcid.org/0000-0002-2915-9328" target=_blank id=mauthor-orcid-6><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-6><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2915-9328</div><sup>6</sup>,&nbsp;</span><span class="">Piero L. Olliaro<sup>6</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 05 Jul 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.14821.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> International Union Against Tuberculosis and Lung Disease, 68 Boulevard Saint Michel, 75006 Paris, France<br/> <sup>2</sup> London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK<br/> <sup>3</sup> International Union Against Tuberculosis and Lung Disease, No. 1 Xindong Road, 100600 Beijing, China<br/> <sup>4</sup> International Union Against Tuberculosis and Lung Disease, South-East Asia Regional Office, C-6 Qutub Institutional Area, 110016 New Delhi, India<br/> <sup>5</sup> AIDS &amp; TB Department, Ministry of Health and Child Care, 2nd Floor, Mukwati Building, Corner Livingstone Avenue and 5th Street, Harare, Zimbabwe<br/> <sup>6</sup> Special Programme for Research and Training in Tropical Disease (TDR), World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland<br/> <p> <div class=margin-bottom> Anthony D. Harries <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Yan Lin <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Ajay M.V. Kumar <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Srinath Satyanarayana <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Kudakwashe C. Takarinda <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Riitta A. Dlodlo <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Rony Zachariah <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Piero L. Olliaro <br/> <span>Roles: </span> Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=13586-35651></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=36150-35652></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The international community has committed to ending the tuberculosis (TB) epidemic by 2030. This will require multi-sectoral action with a focus on accelerating socio-economic development, developing and implementing new tools, and expanding health insurance coverage. Within this broad framework, National TB Programmes (NTPs) are accountable for delivering diagnostic, treatment, and preventive services. There are large gaps in the delivery of these services, and the aim of this article is to review the crucial activities and interventions that NTPs must implement in order to meet global targets and milestones that will end the TB epidemic. The key deliverables are the following: turn End TB targets and milestones into national measurable indicators to make it easier to track progress; optimize the prompt and accurate diagnosis of all types of TB; provide rapid, complete, and effective treatment to all those diagnosed with TB; implement and monitor effective infection control practices; diagnose and treat drug-resistant TB, associated HIV infection, and diabetes mellitus; design and implement active case finding strategies for high-risk groups and link them to the treatment of latent TB infection; engage with the private-for-profit sector; and empower the Central Unit of the NTP particularly in relation to data-driven supportive supervision, operational research, and sustained financing. The glaring gaps in the delivery of TB services must be remedied, and some of these gaps will require new paradigms and ways of working which include patient-centered and higher-quality services. There must also be fast-track ways of incorporating new diagnostic, treatment, and prevention tools into program activities so as to rapidly reduce TB incidence and mortality and meet the goal of ending TB by 2030. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> tuberculosis; world health organization; sustainable development goals; ending the TB epidemic; national tuberculosis programmes; diagnosis; anti-tuberculosis treatment; latent tuberculosis infection </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Anthony D. Harries (<a href="mailto:adharries@theunion.org">adharries@theunion.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Anthony D. Harries </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Harries AD <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Harries AD, Lin Y, Kumar AMV <em>et al.</em> What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030? [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1011 (<a href="https://doi.org/10.12688/f1000research.14821.1" target=_blank>https://doi.org/10.12688/f1000research.14821.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 05 Jul 2018, <b>7</b>(F1000 Faculty Rev):1011 (<a href="https://doi.org/10.12688/f1000research.14821.1" target=_blank>https://doi.org/10.12688/f1000research.14821.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 05 Jul 2018, <b>7</b>(F1000 Faculty Rev):1011 (<a href="https://doi.org/10.12688/f1000research.14821.1" target=_blank>https://doi.org/10.12688/f1000research.14821.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e289>Introduction</h2><p class="" id=d96685e292><i>If you always do what you always did, you will always get what you always got.</i></p><p class="" id=d96685e296>Albert Einstein</p><p class="" id=d96685e299>The Sustainable Development Goals (SDGs), adopted by United Nations (UN) Member States in September 2015, and the World Health Organization (WHO) End TB Strategy, endorsed by the WHO’s 194 Member States in 2014, have a common goal with respect to tuberculosis (TB): to end the global TB epidemic. Targets for meeting this goal include a 90% reduction in TB deaths and an 80% reduction in TB incidence by 2030 compared with 2015: these targets also need to be achieved with no TB-affected families facing catastrophic costs<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. Milestones have been set to help monitor progress along the way (<a href="#T1">Table 1</a>).</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Global milestones and targets for ending tuberculosis by 2030.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d96685e323 class=n-a></a><thead><a name=d96685e325 class=n-a></a><tr><a name=d96685e327 class=n-a></a><th align=left colspan=1 rowspan=2 valign=top><a name=d96685e329 class=n-a></a>Indicators</th><th align=center colspan=2 rowspan=1 valign=top><a name=d96685e332 class=n-a></a>Milestones</th><th align=center colspan=2 rowspan=1 valign=top><a name=d96685e335 class=n-a></a>Targets</th></tr><tr><a name=d96685e339 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d96685e341 class=n-a></a>2020</th><th align=center colspan=1 rowspan=1 valign=top><a name=d96685e344 class=n-a></a>2025</th><th align=center colspan=1 rowspan=1 valign=top><a name=d96685e347 class=n-a></a>SDGs<br class=br>2030</th><th align=center colspan=1 rowspan=1 valign=top><a name=d96685e352 class=n-a></a>End TB<br class=br>2035</th></tr></thead><tbody><a name=d96685e359 class=n-a></a><tr><a name=d96685e361 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e363 class=n-a></a>Percentage reduction in the absolute number of TB<br class=br>deaths (compared with 2015 baseline)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e368 class=n-a></a>35%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e371 class=n-a></a>75%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e374 class=n-a></a>90%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e377 class=n-a></a>95%</td></tr><tr><a name=d96685e381 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e383 class=n-a></a>Percentage reduction in the TB incidence rate<br class=br>(compared with 2015 baseline)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e388 class=n-a></a>20%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e391 class=n-a></a>50%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e394 class=n-a></a>80%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e397 class=n-a></a>90%</td></tr><tr><a name=d96685e401 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e403 class=n-a></a>Percentage of TB-affected households experiencing<br class=br>catastrophic costs due to TB (level in 2015 unknown)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e408 class=n-a></a>0%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e411 class=n-a></a>0%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e414 class=n-a></a>0%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d96685e417 class=n-a></a>0%</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d96685e425 class=n-a></a><p id=d96685e427> SDG, Sustainable Development Goal; TB, tuberculosis. Adapted from reference <a href="#ref-2">2</a>.</p></div></div></div><p class="" id=d96685e437>Since the WHO took the extraordinary step in 1993 of declaring TB a “global emergency”, huge steps have been taken to control this ancient disease, once coined “the captain of all these men of death”<sup><a href="#ref-3">3</a></sup>. The “DOTS” strategy launched by the WHO in 1995, which evolved into the “Stop TB” Strategy a decade later and then the “End TB” Strategy, has provided the successive frameworks and targets for international and national control efforts. In 2000, the Millennium Development Goals (the predecessor to the SDGs) included a TB-specific target (6c) “to halt and reverse TB incidence” by 2015, and this was augmented by two Stop TB Partnership targets to halve TB prevalence and mortality by 2015 compared with levels in 1990. By 2015, TB incidence was halted and reversed, and TB-related mortality (deaths per 100,000 population per year) was decreased by 47% overall between 1990 and 2014<sup><a href="#ref-4">4</a></sup>. TB treatment averted an estimated 49 million deaths globally between 2000 and 2015<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d96685e452>Despite this laudable progress, the disease remains an enormous global public health threat, especially for low- and middle-income countries. In 2016, an estimated 10.4 million new people developed TB and 1.7 million died, making TB the ninth leading cause of death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS<sup><a href="#ref-5">5</a></sup>. Critical problems remain at large. TB control depends on preventing latent TB infection from becoming established or developing into active disease and on diagnosing and treating active disease as soon as it has developed. TB preventive treatment is expanding, but most of those eligible for this intervention are not accessing it. In 2016, only 6.3 million new patients with TB were reported, meaning that 4.1 million (40% of the estimated disease burden) either were not diagnosed or were diagnosed but not notified to national programs<sup><a href="#ref-5">5</a></sup>. Drug-resistant TB grows inexorably. In 2016, there were an estimated 600,000 new patients with resistance to rifampicin (RR-TB), of which 490,000 had resistance to both rifampicin and isoniazid, the two most-effective first-line drugs (multidrug-resistant TB, or MDR-TB). Only 22% of patients with MDR-TB were started on treatment, and of these only 54% were successfully treated. In 2016, HIV-associated TB accounted for 1.03 million patients and was responsible for 374,000 deaths<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d96685e467>Ending the TB epidemic will require multi-sectoral action with a focus on accelerating socio-economic development, developing a new TB vaccine, producing novel diagnostics and medicines for treatment, and expanding health insurance coverage<sup><a href="#ref-6">6</a></sup>. The years 2017 and 2018 were and are respectively landmarks for global efforts to end TB in the era of the SDGs. In Moscow in November 2017, the WHO hosted the first global Ministerial Conference on TB and the aim was to accelerate the implementation of the WHO End TB Strategy<sup><a href="#ref-5">5</a></sup>. September 2018 will see the first UN General Assembly high-level meeting on TB at which a multi-sectoral approach and accountability framework will be agreed upon and endorsed by heads of state.</p><p class="" id=d96685e478>Within this broad framework, National TB Programmes (NTPs) are responsible and accountable for delivering high-quality and effective diagnostic, treatment, and preventive services and ultimately interrupting the transmission of <i>Mycobacterium tuberculosis</i> (<i>MTB</i>) from infected to non-infected persons<sup><a href="#ref-7">7</a></sup>. To this end, the Stop TB Partnership, inspired by the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 treatment targets for HIV care and treatment<sup><a href="#ref-8">8</a></sup>, in 2015 launched 90-(90)-90 TB diagnostic and treatment targets as part of the Global Plan to accelerate the ending of the TB epidemic (<a href="#T2">Table 2</a>)<sup><a href="#ref-9">9</a></sup>. The aim of this article is to review the crucial activities and interventions that NTPs need to implement in order to meet the 90-(90)-90 TB targets and end the TB epidemic.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. 90-(90)-90 People-centered global targets for tuberculosis.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d96685e514 class=n-a></a><tbody><a name=d96685e516 class=n-a></a><tr><a name=d96685e518 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e520 class=n-a></a>• Reach and treat at least 90% of all people with TB<sup><a href="#FN1">a</a></sup><br class=br>• As a part of this approach, reach and treat at least (90%) of the key populations<sup><a href="#FN1">b</a></sup><br class=br>• Achieve at least 90% treatment success for all people diagnosed with TB<sup><a href="#FN1">c</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d96685e541 class=n-a></a><p id=FN1> TB, tuberculosis. <sup>a</sup>Includes people with both drug-susceptible and drug-resistant TB as well as people who require preventive therapy (for example, people living with HIV and those in contact with patients with TB). <sup>b</sup>Includes vulnerable, underserved, and at-risk populations which vary depending on country context. <sup>c</sup>Includes achieving 90% treatment success among people diagnosed with both drug-susceptible and drug-resistant TB as well as people who require TB preventive therapy. Adapted from reference <a href="#ref-9">9</a>.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e564>Turn End TB milestones and targets into measurable numbers</h2><p class="" id=d96685e567>NTPs must work with the WHO to develop, at the national level, absolute numbers for milestones and targets on estimated TB incidence and mortality for 2020, 2025, and 2030 so that these become easily understandable and visible indicators against which genuine progress can be measured. In the next eight years, for example, the annual decline in TB incidence has to accelerate from the current 1.5% per year to 5% per year by 2020 and to 10% per year by 2025<sup><a href="#ref-5">5</a></sup>. The proportion of people who die from TB likewise needs to decrease to 10% by 2020 and to 6.5% by 2025. Translation of global percentage reductions to country target numbers allows NTPs to have benchmarks and to determine in detail how their states, provinces, regions, and districts are performing. Countries that are lagging behind should be given additional support to hasten progress, while those that are doing well need encouragement and praise. This approach is not new and was adopted by Malawi in 2004 when it successfully implemented the WHO’s “3 by 5” initiative for scaling up antiretroviral therapy (ART) country-wide<sup><a href="#ref-10">10</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e581>Optimize systems for prompt and accurate diagnosis of tuberculosis</h2><p class="" id=d96685e584>There are two prongs to the diagnosis of TB: accurate identification of the disease and ascertainment of the drug-susceptibility status of <i>MTB.</i> Microbiological examination of sputum smears for acid-fast bacilli, with or without chest radiography, has long been the mainstay of TB diagnosis in resource-poor countries. However, because this method is diagnostically insensitive and cannot be used to assess drug-susceptibility status, molecular technology is rapidly taking over. The WHO-preferred test is the Xpert MTB/RIF assay (Cepheid Inc., Sunnyvale, CA, USA). This is a highly sensitive, fully-automated, and commercially available nucleic acid amplification test for use with sputum and other bodily specimens<sup><a href="#ref-11">11</a></sup>. The assay requires minimal expertise and has a short sample processing time of 2 hours to confirm the presence of <i>MTB</i> and to detect rifampicin resistance.</p><p class="" id=d96685e597>Xpert MTB/RIF was initially used for high-risk groups, but in 2013 the WHO recommended that the assay be considered the initial diagnostic test for all people requiring investigation for TB<sup><a href="#ref-12">12</a></sup>. Between 2010 and 2016, nearly 6,700 Xpert instruments were procured by NTPs in 130 of 145 countries eligible for concessional pricing, and, in 2016 alone, this included 6.9 million test cartridges<sup><a href="#ref-5">5</a></sup>. These impressive statistics, however, belie major challenges with the use of Xpert MTB/RIF, such as the need for stable and regular electricity, adequate maintenance, and uninterrupted cartridge supplies<sup><a href="#ref-13">13</a></sup>. In many countries, installed instruments are underutilized; the island of Kiribati, which has a significant TB burden, is an illustration of this point<sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d96685e616>NTPs should consider four practical steps to improve systems for TB diagnosis. First, with many programs in resource-poor areas still in the process of scaling up Xpert technology, a mixture of smear microscopy and Xpert MTB/RIF is used. NTPs need to work out how and where these two diagnostic systems are deployed and the most practical and effective algorithms for their use.</p><p class="" id=d96685e619>Second, NTPs need to have accurate and timely records of numbers presenting with presumptive TB, numbers who submit sputum or other bodily specimens for laboratory investigation, and numbers diagnosed with bacteriologically confirmed TB. This cascade should be routinely monitored and is a fertile area for operational research. A recent review in primary care clinics in South Africa showed that 20% of patients with classic TB symptoms were never screened by health-care staff and that 80% of patients who were screened and identified with TB symptoms failed to submit the necessary sputum specimens<sup><a href="#ref-15">15</a></sup>. These system-related deficiencies suggest that much more can be done within the health-care setting to identify patients with presumptive TB and ensure that they are appropriately investigated.</p><p class="" id=d96685e627>Third, depending on the number of modules per Xpert MTB/RIF instrument (the usual instrument has four modules), it is simple to calculate the number of expected assays that should be performed per instrument per month and then to monitor the number of assays actually performed against this target. Such information is critical for evaluating the proper deployment and effective use of these instruments.</p><p class="" id=d96685e630>Finally, NTPs must keep abreast of new developments in molecular technology. Xpert MTB/RIF has its limitations, which include suboptimal sensitivity and a high rate of false positivity in low-prevalence settings. To overcome this, the assay was re-engineered to increase diagnostic sensitivity and improve specificity in the detection of rifampicin resistance. The resulting Xpert MTB/RIF Ultra assay is run on the same instrument as Xpert and requires only a software upgrade<sup><a href="#ref-16">16</a></sup>. In 2017, based on a technical expert consultation, the WHO recommended the use of Xpert MTB/RIF Ultra in all settings as a replacement for Xpert MTB/RIF<sup><a href="#ref-17">17</a></sup>. However, such replacement comes with advantages and disadvantages. A recent multi-center study showed increased sensitivity of Xpert MTB/RIF Ultra, especially in patients with paucibacillary disease and HIV co-infection, but this was at the expense of decreased specificity, especially in those with a history of TB<sup><a href="#ref-18">18</a></sup>. Additional work and research are needed to provide solutions to these problems.</p><p class="" id=d96685e645>Xpert Omni (a portable, battery-operated, single-cartridge, point-of-care device) is currently undergoing field evaluation, and launch is expected in 2019<sup><a href="#ref-19">19</a></sup>. If costs permit (and worryingly these do appear to be rising), this might allow further decentralization of molecular diagnostic technology and improved patient access.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e655>Provide rapid, complete, and effective treatment to all those diagnosed with tuberculosis</h2><p class="" id=d96685e658>All patients diagnosed with TB should receive prompt, complete, and effective treatment with appropriate nutritional and psycho-social support. In practice, this does not happen. In Africa, Asia, and the Western Pacific, between 4% and 38% of patients with laboratory-detected sputum smear-positive or culture-positive TB fail to start treatment<sup><a href="#ref-20">20</a></sup>. This outcome, known as pre-treatment loss to follow-up, appears to be no better with the use of Xpert MTB/RIF, and pre-treatment loss to follow-up varies from 21% in Cameroon to 30% in Myanmar and to 45% in South Africa<sup><a href="#ref-21">21</a>–<a href="#ref-23">23</a></sup>. For patients who do get treated, the turn-around time between confirmed diagnosis and treatment initiation can also be lengthy, compromising individual care and increasing the risk of <i>MTB</i> transmission within families and communities.</p><p class="" id=d96685e675>This disconnection between laboratories, treatment facilities, and patients has to change. District TB officers must be held accountable for linking diagnosed patients to treatment. One simple method is to regularly identify all bacteriologically confirmed TB patients in the laboratory register and check that they have been entered into the patient TB treatment register. In the 1990s, the Malawi NTP adopted this system and set a national performance target that at least 90% of diagnosed patients should start standardized treatment<sup><a href="#ref-24">24</a></sup>. Time between diagnosis and start of treatment should also be monitored, and targets should be set for what constitutes an unacceptable time interval (for example, more than 7 days). Serious consideration should also be paid to report treatment outcomes on all diagnosed TB patients and not just on those registered for treatment, as is the current procedure. A study in Ghana showed that although treatment success of registered patients with TB was high at 87%, this reduced to 54% when diagnosed patients served as the cohort denominator<sup><a href="#ref-25">25</a></sup>. Unless this change is made, NTPs will be unable under routine program conditions to measure the third pillar of the Global TB Plan, namely whether 90% of their diagnosed patients have successfully completed treatment<sup><a href="#ref-9">9</a></sup>.</p><p class="" id=d96685e690>WHO guidelines (2009 and 2017) specify that new patients with drug-susceptible TB be treated with a standardized regimen of isoniazid and rifampicin for 6 months, supplemented with pyrazinamide and ethambutol for the first 2 months<sup><a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup>. Standardization of medication dosages by body weight, use of fixed-dose combinations and patient treatment kits, and insistence that drugs be given under direct observation (directly observed therapy, or DOT) have facilitated treatment administration and improved patient adherence to medication. Community- or home-based DOT is recommended, and DOT by trained community volunteers/workers or formal health-care workers is preferred over DOT that is administered by family members. This system, which is followed by NTPs worldwide, has contributed to high treatment success rates of registered patients, and the latest outcome data show a global treatment success of 83%<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d96685e704>However, there is room for improvement. Treatment outcome definitions were revised by the WHO in 2013 (<a href="#T3">Table 3</a>)<sup><a href="#ref-28">28</a></sup>. “Not evaluated” is an outcome given to a patient for whom no treatment outcome is assigned, and rates of “not evaluated” can be high. In the 2013 WHO African region cohort, 9% of patients with TB were classified as “not evaluated”, impacting negatively on the overall treatment success rate<sup><a href="#ref-29">29</a></sup>. “Not evaluated” includes patients who are transferred out to another treatment unit and whose treatment outcome is unknown. Transfers during anti-TB treatment are common and often are associated with no treatment outcome in the TB treatment register<sup><a href="#ref-30">30</a>,<a href="#ref-31">31</a></sup>. District TB officers, using mobile phones and other modern communication methods, can significantly reduce this correctable adverse outcome and ensure that all of their transferred-out patients have a documented outcome in the register.</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Definitions of treatment outcomes for patients with drug-susceptible tuberculosis.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d96685e737 class=n-a></a><thead><a name=d96685e739 class=n-a></a><tr><a name=d96685e741 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d96685e743 class=n-a></a>Outcome</th><th align=left colspan=1 rowspan=1><a name=d96685e746 class=n-a></a>Definition</th></tr></thead><tbody><a name=d96685e751 class=n-a></a><tr><a name=d96685e753 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e755 class=n-a></a>Cure</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e758 class=n-a></a>A bacteriologically confirmed TB patient at the beginning of treatment who was found to be smear- or culture-<br class=br>negative in the last month of treatment and on at least one previous occasion</td></tr><tr><a name=d96685e764 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e766 class=n-a></a>Treatment completed</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e769 class=n-a></a>A TB patient who completed treatment without evidence of failure but with no record to show that sputum smear<br class=br>or culture results in the last month of treatment and on at least one previous occasion were negative, either<br class=br>because the tests were not done or because the results are unavailable</td></tr><tr><a name=d96685e777 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e779 class=n-a></a>Treatment failure</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e782 class=n-a></a>A TB patient whose sputum smear or culture is positive at month 5 or later during treatment</td></tr><tr><a name=d96685e786 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e788 class=n-a></a>Died</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e791 class=n-a></a>A TB patient who dies for any reason before starting or during the course of treatment</td></tr><tr><a name=d96685e795 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e797 class=n-a></a>Lost to follow-up</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e800 class=n-a></a>A TB patient who did not start treatment or whose treatment was interrupted for two consecutive months or more</td></tr><tr><a name=d96685e805 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e807 class=n-a></a>Not evaluated</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e810 class=n-a></a>A TB patient for whom no treatment outcome is assigned; this includes patients “transferred-out” to another<br class=br>treatment unit as well as patients for whom the treatment outcome is unknown to the reporting unit</td></tr><tr><a name=d96685e816 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e818 class=n-a></a>Treatment success</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e821 class=n-a></a>The sum of <i>cured</i> and <i>treatment completed</i></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d96685e834 class=n-a></a><p id=d96685e836> TB, tuberculosis. Adapted from reference <a href="#ref-28">28</a>.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e848>Implement and monitor effective infection control practices</h2><p class="" id=d96685e851>Infection control is the basis for preventing exposure to <i>MTB</i> among non-infected individuals in health facilities and other congregate settings. Health facility exposure accounts for a significant proportion of total TB infection risk for patients who repeatedly attend health facilities for chronic care in high-TB burden settings<sup><a href="#ref-32">32</a></sup>. Health-care staff are similarly at high risk<sup><a href="#ref-33">33</a></sup>. In the high-HIV prevalence areas of Southern Africa, devastating and lethal outbreaks of drug-resistant TB have occurred in the open and crowded hospital wards and out-patient facilities<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>.</p><p class="" id=d96685e872>NTPs must pay attention to the WHO TB infection control guidelines which focus on early identification, isolation, and treatment of those with presumptive TB, infrastructure modifications (such as enlarged windows, open skylights, and open-air waiting rooms) to ensure appropriate natural ventilation and air flow, use of ultraviolet germicidal irradiation fixtures (if applicable and affordable), better organization to avoid patient congestion, and provision of personal protective measures for health workers (<a href="#T4">Table 4</a>)<sup><a href="#ref-36">36</a></sup>. For drug-resistant TB, the introduction of the FAST strategy (find cases actively, separate safely, and treat effectively) has been associated with a significant reduction of hospital-based acquisition of MDR-TB in the Russian Federation<sup><a href="#ref-37">37</a></sup>, and this approach should be encouraged in other countries. An important monitoring indicator for effective implementation within health facilities is the number and proportion of health-care workers who develop TB each year, and this should be routinely reported by NTPs.</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Infection control guidelines for reducing transmission of <i>Mycobacterium tuberculosis</i> in health facilities.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d96685e900 class=n-a></a><tbody><a name=d96685e902 class=n-a></a><tr><a name=d96685e904 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e906 class=n-a></a><b>Facility-level measures</b><br class=br>•&nbsp;&nbsp;&nbsp;Redesign the use of available spaces, renovate existing facilities, or construct new facilities<br class=br>•&nbsp;&nbsp;&nbsp;Conduct on-site surveillance of TB in health workers<br class=br>•&nbsp;&nbsp;&nbsp;Discuss TB transmission with health workers, patients, and visitors<br class=br>•&nbsp;&nbsp;&nbsp;Monitor the package of TB infection control measures</td></tr><tr><a name=d96685e919 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e921 class=n-a></a><b>Administrative measures</b><br class=br>•&nbsp;&nbsp;&nbsp;Promptly identify people with TB symptoms, separate potentially infectious and confirmed infectious patients<br class=br>from others, institute cough etiquette and respiratory hygiene, and minimize time spent in health-care facilities<br class=br>•&nbsp;&nbsp;&nbsp;Provide prevention and care interventions for health workers, including HIV prevention, antiretroviral therapy,<br class=br>and isoniazid preventive therapy for HIV-positive health workers</td></tr><tr><a name=d96685e934 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e936 class=n-a></a><b>Environmental protection</b><br class=br>•&nbsp;&nbsp;&nbsp;Ensure good natural ventilation (open windows and doors, enlarged or additional windows, and open skylights<br class=br>for cross-ventilation)<br class=br>•&nbsp;&nbsp;&nbsp;Use ultraviolet germicidal irradiation fixtures (if applicable and affordable, especially in cold climates when<br class=br>windows and skylights remain shut)</td></tr><tr><a name=d96685e949 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e951 class=n-a></a><b>Personal protection</b><br class=br>•&nbsp;&nbsp;&nbsp;Use particulate respirators especially for managing drug-resistant TB</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d96685e962 class=n-a></a><p id=d96685e964> TB, tuberculosis. Adapted from reference <a href="#ref-36">36</a>.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e977>Diagnose and promptly treat drug-resistant tuberculosis</h2><p class="" id=d96685e980>Both RR/MDR-TB require prolonged treatment (traditionally up to 24 months) with second-line anti-TB drugs, which are less effective and more costly and are associated with more adverse events compared with first-line drugs (<a href="#T5">Table 5</a>)<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>. About 10% of patients with MDR-TB have additional resistance to fluoroquinolones or second-line injectable agents (termed extensively drug-resistant TB, or XDR-TB) or both. XDR-TB is best treated with regimens that include bedaquiline and linezolid, but even so about one-third of treated XDR-TB patients have unfavorable treatment outcomes of death, failure, and loss to follow-up<sup><a href="#ref-40">40</a></sup>. These adverse treatment outcomes contribute to a growing and dangerous problem of patients with programmatically incurable TB. Globally, in 2016, 4% of new cases and 19% of previously treated TB cases had MDR-TB, and nearly half of the world’s cases are in China, India, and the Russian Federation<sup><a href="#ref-5">5</a></sup>. Some countries in Eastern Europe and Central Asia have alarming levels of disease; a national prevalence survey in the Ukraine found the proportions of MDR-TB among new and previously treated cases to be 24% and 58%, respectively<sup><a href="#ref-41">41</a></sup>.</p><a name=T5 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 5. Second-line drugs recommended for the treatment of multidrug-resistant tuberculosis.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d96685e1016 class=n-a></a><thead><a name=d96685e1018 class=n-a></a><tr><a name=d96685e1020 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d96685e1022 class=n-a></a>Drug class</th><th align=left colspan=1 rowspan=1 valign=top><a name=d96685e1025 class=n-a></a>Name of drug</th></tr></thead><tbody><a name=d96685e1030 class=n-a></a><tr><a name=d96685e1032 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1034 class=n-a></a>Fluoroquinolones</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1037 class=n-a></a>Levofloxacin<br class=br>Moxifloxacin<br class=br>Gatifloxacin</td></tr><tr><a name=d96685e1045 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1047 class=n-a></a>Second-line injectable agents</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1050 class=n-a></a>Amikacin<br class=br>Capreomycin<br class=br>Kanamycin<br class=br>(Streptomycin)</td></tr><tr><a name=d96685e1060 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1062 class=n-a></a>Other core second-line agents</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1065 class=n-a></a>Ethionamide/Prothionamide<br class=br>Cycloserine/Terizidone<br class=br>Linezolid<br class=br>Clofazimine</td></tr><tr><a name=d96685e1075 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1077 class=n-a></a>Add-on agents</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1080 class=n-a></a>Bedaquiline<br class=br>Delamanid<br class=br>p-aminosalicylic acid<br class=br>Imipenem-cilastatin<sup><a href="#TFN2">a</a></sup><br class=br>Meropenem<sup><a href="#TFN2">a</a></sup><br class=br>Amoxicillin-clavulanate<sup><a href="#TFN2">a</a></sup><br class=br>(Thioacetazone)<sup><a href="#TFN2">b</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d96685e1113 class=n-a></a><p id=TFN2> <sup>a</sup>Carbapenems and clavulanate are meant to be used together: clavulanate is available only in formulations combined with amoxicillin. <sup>b</sup>HIV status must be confirmed as negative before thioacetazone is started. Adapted from references <a href="#ref-38">38</a> and <a href="#ref-39">39</a>.</p></div></div></div><p class="" id=d96685e1132>Countries with known high levels of MDR-TB should test all new and previously treated cases of TB for rifampicin resistance by using Xpert MTB/RIF. Those with lower drug-resistance burdens must examine their resources and decide, for example, whether to prioritize all previously treated TB cases for Xpert MTB/RIF and work out when to use Xpert MTB/RIF on new cases that are diagnosed through smear microscopy.</p><p class="" id=d96685e1135>Many countries still like to confirm their RR-TB Xpert results with conventional culture and drug sensitivity testing (CDST) in national reference laboratories, and this requires the transportation of sputum specimens from peripheral health facilities. Wherever this system has been assessed, it does not function<sup><a href="#ref-42">42</a>–<a href="#ref-45">45</a></sup>, and transportation is the major bottleneck. Other obstacles include the formation of committees to approve MDR-TB treatment and a battery of hematological and biochemical tests which are considered necessary in all settings before treatment can be started. Although these procedures may be necessary when new drugs such as bedaquiline and delamanid are introduced in programmatic settings, they can contribute to diagnosed patients either failing to start treatment or experiencing significant delays. NTPs must decide what to do: whether to streamline the preparatory phase for starting MDR-TB treatment and whether to maintain but fix their national reference laboratory CDST systems or alternatively dispense with CDST and focus on scaling up and decentralizing their diagnostic molecular technology.</p><p class="" id=d96685e1146>This is not an easy decision. The WHO has recently recommended a new short-course regimen of 9 to 12 months for MDR-TB provided that patients have not been treated with second-line drugs and/or have had resistance to fluoroquinolones and second-line injectable agents excluded<sup><a href="#ref-46">46</a></sup>. This regimen in eligible patients is well tolerated and, according to observational studies, has excellent treatment success rates both in Asia and in Africa<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. Definitive and published results from the STREAM 1 randomized controlled trial comparing the 9-month regimen with a 24-month regimen are awaited.</p><p class="" id=d96685e1160>Currently, conventional CDST and molecular line probe assays (LPAs) performed in laboratories are the only ways of obtaining information on second-line drug resistance. LPAs are more rapid than conventional phenotypic drug sensitivity testing (DST) methods, allowing a rapid diagnosis of either MDR-TB or XDR-TB within 3 days either from sputum submission or after obtaining a pure culture of <i>MTB</i>. LPAs are therefore recommended by the WHO as the initial laboratory test instead of phenotypic DST for diagnosing MDR-TB or XDR-TB<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. Good functioning and well-resourced laboratories plus well-trained, skilled laboratory technicians are necessary for LPAs to perform well, and thus these assays are generally used only in national reference laboratories.</p><p class="" id=d96685e1173>However, a new automated, cartridge-based assay has been developed that accurately detects <i>MTB</i> mutations associated with resistance to isoniazid, fluoroquinolones, and aminoglycosides, and this holds promise as a rapid point-of-care test to guide therapeutic decisions for patients with drug-resistant TB<sup><a href="#ref-51">51</a></sup>. This will also facilitate the identification of isoniazid mono-resistance, which may be found in 10% or more of patients and which currently needs conventional CDST or laboratory-based LPA for diagnosis. Isoniazid mono-resistance may be associated with worse treatment outcomes<sup><a href="#ref-52">52</a></sup>, and the WHO recommends that high levels of isoniazid mono-resistance warrant a change of regimen to rifampicin, ethambutol, pyrazinamide, and levofloxacin<sup><a href="#ref-53">53</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e1194>Diagnose and treat HIV infection and diabetes mellitus</h2><div class=section><a name=d96685e1197 class=n-a></a><h3 class=section-title>HIV infection</h3><p class="" id=d96685e1202>The HIV epidemic has hampered TB control efforts globally, especially in the high-HIV prevalence areas of Southern and Eastern Africa. Case fatality rates are several times higher in patients with HIV-associated TB compared with those who have just TB<sup><a href="#ref-54">54</a></sup>. ART, however, results in excellent immunological and virological responses and a reduction in mortality risk of 64% to 95%<sup><a href="#ref-55">55</a></sup>. Cotrimoxazole preventive therapy (CPT) augments this response and, when combined with ART, further reduces mortality and morbidity<sup><a href="#ref-56">56</a></sup>.</p><p class="" id=d96685e1217>HIV testing is the gateway to such integrated care, but in 2016 only 57% of notified TB cases globally had a documented HIV test; the figure was highest in the Africa region at 82%<sup><a href="#ref-5">5</a></sup>. The WHO recommends ART for all HIV-positive TB patients within the first 8 weeks of starting anti-TB treatment but, although this has improved in recent years, was still only 85% in 2016<sup><a href="#ref-5">5</a></sup>. In 2014, 87% of HIV-positive TB cases globally received CPT<sup><a href="#ref-29">29</a></sup>.</p><p class="" id=d96685e1232>NTPs must be bold and aim for 100% HIV testing uptake and 100% CPT and ART for those diagnosed HIV-positive. How this is best achieved is up to countries and depends on how well TB and HIV/AIDS services are decentralized along with the needed clinic infrastructure and trained health-care staff. Approaches need to be contextual and innovative, preferably aiming for a “one-stop-shop” service that integrates TB and HIV care<sup><a href="#ref-57">57</a></sup>.</p></div><div class=section><a name=d96685e1240 class=n-a></a><h3 class=section-title>Diabetes mellitus</h3><p class="" id=d96685e1245>People with diabetes mellitus (DM) have a three-times-higher risk of TB compared with the general population<sup><a href="#ref-58">58</a>–<a href="#ref-60">60</a></sup>. Both type 1 and type 2 DM increase this risk, but as type 2 disease accounts for 90% or more of the global cases of DM, this type of DM dominates the interaction. In 2012, it was estimated that the number of adult TB cases associated with DM was just over 1 million, similar to what was observed at that time for HIV-associated TB<sup><a href="#ref-60">60</a></sup>.</p><p class="" id=d96685e1259>DM adversely affects TB treatment outcomes<sup><a href="#ref-61">61</a></sup>. The reasons are not completely understood but include the immunosuppressive and biochemical effects of DM itself, drug–drug interactions, adverse events from medications, suboptimal adherence, and reduced bio-availability of the drugs. The risk of death during TB treatment is almost doubled among those with DM, and this risk increases to about five times when adjustments are made for age and other potential confounders<sup><a href="#ref-61">61</a></sup>. Cardiovascular disease could explain an increased rate of deaths within months after starting anti-TB treatment<sup><a href="#ref-62">62</a></sup> and the much higher death rates among DM patients who smoke<sup><a href="#ref-63">63</a></sup>. The risks of relapse TB in those who have completed anti-TB treatment are also higher among those with DM compared with those without<sup><a href="#ref-61">61</a></sup>, and this further adds to the disease burden. DM is also an independent risk factor for the development of MDR-TB<sup><a href="#ref-64">64</a></sup>.</p><p class="" id=d96685e1287>Globally, the prevalence of DM among patients with TB ranges from 1.9% to 45%, and risk factors are older age, urban residence, sedentary life-style, and having a family history of DM<sup><a href="#ref-65">65</a></sup>. The WHO and the International Union Against Tuberculosis and Lung Disease now recommend that all patients with TB be systematically screened for DM<sup><a href="#ref-66">66</a></sup>, and implementation research within the general health services in India and China has shown the feasibility and effectiveness of screening for DM at the time of registering TB patients for treatment<sup><a href="#ref-67">67</a>,<a href="#ref-68">68</a></sup>. There is some evidence that improved management of DM and the use of metformin as the oral anti-diabetes medication reduce the risk of death during TB treatment, although these encouraging findings need confirmation<sup><a href="#ref-69">69</a>,<a href="#ref-70">70</a></sup>. With the global pandemic of DM escalating and seemingly out of control<sup><a href="#ref-71">71</a></sup>, NTPs need to keep up to date with advances in the field of DM-associated TB and seriously consider setting up routine screening and care for DM.</p></div><div class=section><a name=d96685e1317 class=n-a></a><h3 class=section-title>Design and implement active case finding strategies for high-risk and vulnerable groups</h3><p class="" id=d96685e1322>In most TB endemic settings, TB case detection is based on passive case finding, namely waiting for symptomatic patients to seek health-care. This strategy, as shown consistently in TB prevalence surveys, is inadequate to detect the substantial burden of undiagnosed TB in the community<sup><a href="#ref-72">72</a></sup>. Active case finding (ACF) is an additional approach, which proactively seeks to identify patients with TB.</p><p class="" id=d96685e1329>Mathematical models suggest that ACF could increase TB case finding, and the WHO has provided guidelines for the systematic and active screening of high-risk groups (<a href="#T6">Table 6</a>)<sup><a href="#ref-73">73</a>,<a href="#ref-74">74</a></sup>. In one review, the yields of newly diagnosed TB through ACF were 0.7% in population-based community surveys, 2.2% in contact-tracing studies, 2.3% in mines, 2.5% in prisons, 8.2% in medical and ART clinics, and 8.5% in HIV voluntary and counselling services<sup><a href="#ref-75">75</a></sup>. Prisons and health-care facilities in low-resource settings are high-risk areas for intense TB transmission<sup><a href="#ref-76">76</a>,<a href="#ref-77">77</a></sup>, and ACF combined with other TB control measures would help to considerably reduce TB incidence in these settings. Interest has recently developed about screening people with DM for TB. There are no global data, but two large studies from China and India within the routine health services found that the yields of TB were significantly higher than those found from passive case finding amongst the general population<sup><a href="#ref-78">78</a>,<a href="#ref-79">79</a></sup>.</p><a name=T6 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 6. World Health Organization recommendations on risk groups for screening.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d96685e1371 class=n-a></a><thead><a name=d96685e1373 class=n-a></a><tr><a name=d96685e1375 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d96685e1377 class=n-a></a>Strong recommendations<sup><a href="#TFN3">a</a></sup></th></tr></thead><tbody><a name=d96685e1385 class=n-a></a><tr><a name=d96685e1387 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1389 class=n-a></a>Household and other close contacts should be systematically screened for active TB</td></tr><tr><a name=d96685e1393 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1395 class=n-a></a>People living with HIV should be screened for TB at each visit to a health facility</td></tr><tr><a name=d96685e1399 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1401 class=n-a></a>Current and past workers in workplaces with silica should be screened for active TB</td></tr><tr><a name=d96685e1405 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d96685e1407 class=n-a></a><b>Conditional recommendations</b><sup><a href="#TFN3">b</a></sup></th></tr><tr><a name=d96685e1415 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1417 class=n-a></a>Systematic screening for active TB should be considered in prisons</td></tr><tr><a name=d96685e1422 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1424 class=n-a></a>Systematic screening for active TB should be considered in those with fibrotic chest radiograph lesions</td></tr><tr><a name=d96685e1428 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1430 class=n-a></a>Systematic screening for active TB should be considered for those seeking or in health-care</td></tr><tr><a name=d96685e1434 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1436 class=n-a></a>Systematic screening for active TB should be considered in other high-risk groups; these include<br class=br>people living in urban slums, homeless people, people living in remote areas, some indigenous<br class=br>populations, and migrants/refugees</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=TFN3 class=n-a></a><p id=d96685e1450> TB, tuberculosis. <sup>a</sup>A strong recommendation is one in which the desirable effects clearly outweigh the undesirable effects and for which screening is judged to be feasible, acceptable, and affordable in all settings. <sup>b</sup>A conditional recommendation is one in which the desirable effects probably outweigh the undesirable effects. Adapted from reference <a href="#ref-74">74</a>.</p></div></div></div><p class="" id=d96685e1465>To reduce the “missing 4 million TB patients”, NTPs will have to take up ACF, but the scale and focus of what can be done must be contextualized and will be limited by available resources. People living with HIV (PLHIV) and household contacts are easily identifiable high-risk targets and they should be prioritized.</p><p class="" id=d96685e1469>Amongst PLHIV, systematic TB screening (termed intensified case finding) is now an accepted part of the package of care. In 2016, 88,200 (7%) of the 1.3 million PLHIV newly enrolled in HIV care were diagnosed with TB<sup><a href="#ref-5">5</a></sup>, although this figure probably underestimates the true burden of TB in this population. Disseminated TB which is more prevalent in those with advanced immunodeficiency is difficult to diagnose in most health-care facilities in resource-poor settings, and autopsy studies show that much of it is diagnosed post-mortem and not recognized or identified during life<sup><a href="#ref-80">80</a></sup>. For sick, immunocompromised patients, there is a promising bedside test involving measurement of urine lipoarabinomannan (LAM), one of the cell wall lipopolysaccharide components of <i>MTB.</i> The urine test can be carried out with a Determine TB-LAM test strip (Alere, Waltham, MA, USA) with results in 30 minutes. Specificity is high and sensitivity increases as CD4 cell counts decrease to below 100 cells/µL<sup><a href="#ref-81">81</a></sup>. Bedside urine LAM (with a positive result guiding the start of anti-TB treatment) on HIV-infected adults admitted to hospital in several African countries resulted in a decrease in mortality at 2 months<sup><a href="#ref-82">82</a></sup>. Xpert MTB/RIF can also be used on urine specimens to identify HIV-infected hospitalized patients with TB<sup><a href="#ref-83">83</a></sup>. A new screening approach in Malawi and South Africa showed that testing people living with HIV and admitted to hospital with urine LAM and urine Xpert MTB/RIF in addition to sputum Xpert MTB/RIF resulted in increased overall TB diagnosis and treatment and reduced mortality in key subgroups<sup><a href="#ref-84">84</a></sup>. Sick HIV-infected patients with pulmonary and disseminated TB often cannot cough up sputum, and the use of urine as a suitable and easy-to-collect specimen for investigation is a novel step forward.</p><p class="" id=d96685e1500>For years, NTPs have tried, with limited success, to screen household contacts of index smear-positive TB patients, focusing on children younger than 5 years of age. A recent systematic review showed that all household contacts (including adults) are at high risk of developing TB<sup><a href="#ref-85">85</a></sup>. A cluster randomized trial in Vietnam, with repeated visits to households and assessments by symptoms, physical examination, and chest radiography, has shown the undoubted benefit and high yield of this ACF approach<sup><a href="#ref-86">86</a></sup>. NTPs must seriously consider implementing and monitoring this ACF activity.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e1515>Treat latent tuberculosis infection in high-risk groups</h2><p class="" id=d96685e1518>ACF aims to identify amongst high-risk groups those with undiagnosed active TB and at the same time this approach can be used to identify and treat those with latent TB infection (LTBI) to prevent them from developing active disease. Thus, ACF is linked to the treatment of LTBI, and the two high-priority groups for the intervention are the same: PLHIV and household contacts of patients with TB. LTBI is diagnosed by the tuberculin skin test or interferon-gamma release assay<sup><a href="#ref-87">87</a></sup>. Both tests are challenging to use in programmatic settings and this has often proven to be a bottleneck to treating LTBI<sup><a href="#ref-88">88</a></sup>. Updated guidance from the WHO on the programmatic management of LTBI may help to move forward this important but generally neglected aspect of TB control (<a href="#T7">Table 7</a>)<sup><a href="#ref-89">89</a></sup>.</p><a name=T7 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 7. Guidance for diagnosing and treating latent tuberculosis infection.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d96685e1547 class=n-a></a><tbody><a name=d96685e1549 class=n-a></a><tr><a name=d96685e1551 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1553 class=n-a></a>At-risk populations for LTBI testing and<br class=br>treating</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1558 class=n-a></a>Adults, adolescents, children, and infants living with HIV<br class=br> <br class=br>HIV-negative household contacts of persons with bacteriologically confirmed TB<br class=br>(children, adolescents, and adults)<br class=br> <br class=br>Other HIV-negative at-risk groups, according to resources</td></tr><tr><a name=d96685e1572 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1574 class=n-a></a>Testing for LTBI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1577 class=n-a></a>Tuberculin skin test (TST) or interferon-gamma release assay (IGRA) wherever possible<br class=br> <br class=br>People living with HIV with a positive test benefit more from preventive treatment: where<br class=br>testing is possible, this can be used to identify such individuals<br class=br> <br class=br>TST or IGRA is not a requirement for initiating preventive treatment in people living with<br class=br>HIV or child household contacts younger than 5 years of age</td></tr><tr><a name=d96685e1594 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1596 class=n-a></a>Treatment options for LTBI </td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1599 class=n-a></a>Isoniazid monotherapy daily for 6 months<br class=br> <br class=br>Rifampicin and isoniazid daily for 3 months as alternative to isoniazid<br class=br> <br class=br>Rifapentine and isoniazid weekly for 3 months as alternative to isoniazid<br class=br> <br class=br>Isoniazid monotherapy daily for at least 36 months in people living with HIV in high-TB<br class=br>burden settings, regardless of whether they are receiving antiretroviral therapy</td></tr><tr><a name=d96685e1618 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1620 class=n-a></a>Preventive therapy for contacts of<br class=br>patients with multidrug-resistant TB</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1625 class=n-a></a>Treatment options based on individual risk assessment; strongly consider use of<br class=br>levofloxacin or moxifloxacin</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d96685e1635 class=n-a></a><p id=d96685e1637> LTBI, latent tuberculosis infection; TB, tuberculosis. Adapted from reference <a href="#ref-89">89</a>.</p></div></div></div><p class="" id=d96685e1646>PLHIV deserve special mention. ART reverses the immune dysfunction associated with HIV and, as a result, has a potent TB-preventive effect<sup><a href="#ref-90">90</a></sup>. At the program level, the increasing ART coverage in people living with HIV in Swaziland, Zimbabwe, and Malawi has been associated with a decrease in national TB case notification rates for both HIV-positive and HIV-negative persons<sup><a href="#ref-91">91</a>–<a href="#ref-93">93</a></sup>. Randomized controlled trials have shown that the effects of ART in reducing TB incidence may be augmented with the addition of isoniazid preventive therapy (IPT)<sup><a href="#ref-94">94</a>,<a href="#ref-95">95</a></sup>. There is further evidence to suggest that in high-TB exposure environments IPT might have to be given indefinitely for sustained benefit: in this context, it is likely that IPT prevents new infection or reinfection from developing into active disease<sup><a href="#ref-96">96</a></sup>. The number of PLHIV who received IPT in 2016 was 940,269; the largest proportion (41%) came from South Africa<sup><a href="#ref-5">5</a></sup>. Despite progress in some other countries (for example, Malawi, Zimbabwe, and Mozambique), much remains to be done. NTPs need to liaise closely with National HIV/AIDS programs in this regard and decide whether and how best to scale up IPT alongside ART.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e1678>Engage with the private-for-profit sector</h2><p class="" id=d96685e1681>Many resource-poor countries have large and expanding private-for-profit health sectors, and many people with TB seek and receive care from private providers. This is especially so in Asia, but it is also a growing challenge in other parts of the world, including sub-Saharan Africa<sup><a href="#ref-97">97</a>,<a href="#ref-98">98</a></sup>. In recent years, the WHO has begun to address the issue of private-for-profit providers in TB prevention and care through an evolving global strategy called Public-Private Mix (PPM)<sup><a href="#ref-98">98</a></sup>. Central to the concept of PPM and the delivery of quality TB care is the mix of “clinical tasks” (referrals of symptomatic patients, diagnosis, and prescribing treatment) and “public health tasks” (quality assurance, patient follow-up and support, recording, and reporting) and the linkage of private sector providers to local public sector TB programs. Since 2009, high-TB burden countries have reported on the contribution of PPM to TB case notifications, and in 2016 this was approximately 17% in India, 26% in Pakistan, 28% in Bangladesh, and 16% in Myanmar<sup><a href="#ref-5">5</a></sup>. These reports, however, do not reflect ground realities where PPM is often limited to urban areas and a small proportion of targeted providers<sup><a href="#ref-98">98</a></sup>. PPM must become an important partner of NTPs; the persisting challenges and potential ways of improving the service are outlined in <a href="#T8">Table 8</a>. New guidance provided by the WHO in 2017 should help in this regard<sup><a href="#ref-99">99</a></sup>.</p><a name=T8 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 8. Challenges and potential solutions for scaling up private-public mix.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d96685e1722 class=n-a></a><thead><a name=d96685e1724 class=n-a></a><tr><a name=d96685e1726 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d96685e1728 class=n-a></a>Challenges</th></tr></thead><tbody><a name=d96685e1733 class=n-a></a><tr><a name=d96685e1735 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1737 class=n-a></a>Overburdened TB Programs</td></tr><tr><a name=d96685e1741 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1743 class=n-a></a>Fragmented private sector with limited capacity to undertake non-clinical tasks</td></tr><tr><a name=d96685e1747 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1749 class=n-a></a>Weak capacity of public sector to oversee and manage contracts with private organizations</td></tr><tr><a name=d96685e1753 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1755 class=n-a></a>Agreed regulations (e.g. mandatory TB case notifications) are not enforced</td></tr><tr><a name=d96685e1759 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1761 class=n-a></a>Insufficient financing</td></tr><tr><a name=d96685e1766 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d96685e1768 class=n-a></a>Potential solutions</th></tr><tr><a name=d96685e1772 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1774 class=n-a></a>Get governments to commit to invest in the private sector</td></tr><tr><a name=d96685e1778 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1780 class=n-a></a>Consider the financing of private-public mix through universal health coverage</td></tr><tr><a name=d96685e1784 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1786 class=n-a></a>Set up permanent working linkages between TB programs and private health facilities</td></tr><tr><a name=d96685e1790 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1792 class=n-a></a>Use intermediary organizations to design, manage, and supervise contracts</td></tr><tr><a name=d96685e1796 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1798 class=n-a></a>Engage in business-friendly approaches using smart application of new digital technologies</td></tr><tr><a name=d96685e1803 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1805 class=n-a></a>Enforce regulations (mandatory TB case notifications through web-based systems: restrictions<br class=br>on private over-the-counter sales of anti-TB drugs)</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d96685e1815 class=n-a></a><p id=d96685e1817> TB, tuberculosis. Adapted from references <a href="#ref-97">97</a> and <a href="#ref-98">98</a>.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e1832>Empower and strengthen the central unit of the National TB Programme</h2><p class="" id=d96685e1835>NTPs need a strong central unit to provide leadership, planning, training, drug and consumables forecasting, procurement, budgeting, supervision, monitoring and evaluation, and operational research. Ways to integrate TB program activities with other disease-related areas such as HIV/AIDS and DM need to be developed and implemented. NTPs also need to engage regularly with other stakeholders and government departments to make a strong case for reducing poverty and overcrowding and tackling the other key social determinants of TB.</p><p class="" id=d96685e1838>Three areas need emphasis: supervision, research, and finances. Regular, supportive, and structured data-driven supervision coordinated by the central unit is essential to TB control. Supervision within communicable disease control programs helps to check whether guidelines are implemented, drug stocks are sound, records are accurate, and cohort analysis at peripheral levels is correct and meaningful<sup><a href="#ref-7">7</a>,<a href="#ref-100">100</a>,<a href="#ref-101">101</a></sup>. In all of this, supervisors must recognize the potentially perverse nature of targets and ensure that NTPs do not drown in fake numbers<sup><a href="#ref-102">102</a></sup>.</p><p class="" id=d96685e1855>Operational research needs to be firmly embedded within the NTP, as this enables programs to carry out local research that contributes to knowledge, tools, interventions, and strategies that can enhance the quality and coverage of service delivery and help inform better policy and practice<sup><a href="#ref-103">103</a>,<a href="#ref-104">104</a></sup>. The placement of operational research fellows within the central unit of NTPs greatly facilitates the implementation and value of this work<sup><a href="#ref-105">105</a>,<a href="#ref-106">106</a></sup>. NTPs must also form partnerships with academia to facilitate the conduct of meaningful clinical or cluster randomized trials, as demonstrated by the recent household contact assessment in Vietnam<sup><a href="#ref-86">86</a></sup>.</p><p class="" id=d96685e1876>In 2017, most of the funding for TB control efforts was provided by domestic sources (84% of the global total of USD $6.9 billion), although in low-income countries international donor funding, mainly through the Global Fund to fight AIDS, Tuberculosis and Malaria, exceeded domestic funding and this is likely to remain the case<sup><a href="#ref-5">5</a></sup>. Development assistance for health is unlikely to increase in the future, so NTPs need to advocate strongly for domestic funding, ensure that spending is efficient and not wasteful of resources, and keep abreast of new innovative international financing instruments which can benefit global health<sup><a href="#ref-107">107</a></sup>. NTPs in low- and middle-income countries need to emphasize that the diagnosis and treatment of drug-sensitive and drug-resistant TB are very cost-effective when compared with the economic cost and productivity losses that may result from the disease<sup><a href="#ref-108">108</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e1894>Conclusions</h2><p class="" id=d96685e1897>NTPs on their own cannot end the global TB epidemic, which will require accelerated socio-economic development, poverty alleviation, social protection, actions on other determinants of TB, strengthening of health systems, and expansion of universal health coverage. For this multi-sectoral response, there will need to be close engagement of communities, civil society organizations, the private sector, and different government ministries. New tools for preventing, diagnosing, and treating TB are also urgently needed<sup><a href="#ref-6">6</a></sup>.</p><p class="" id=d96685e1904>Nevertheless, NTPs play a crucial role. This article has highlighted the basic TB control principles that need to be adhered to, not just in planning but also in implementation. The glaring gaps in the delivery of diagnostic, treatment, and preventive services along with our remedial recommendations are summarized in <a href="#T9">Table 9</a>. The quality of delivered care often falls short of international standards in both public and private sectors, and NTPs must step up to the plate, systematically measure and improve quality of care, and invest in quality improvement programs<sup><a href="#ref-109">109</a></sup>.</p><a name=T9 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 9. Challenges and recommendations for National TB Programmes.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d96685e1925 class=n-a></a><thead><a name=d96685e1927 class=n-a></a><tr><a name=d96685e1929 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d96685e1931 class=n-a></a>Category</th><th align=left colspan=1 rowspan=1 valign=top><a name=d96685e1934 class=n-a></a>Challenges</th><th align=left colspan=1 rowspan=1 valign=top><a name=d96685e1937 class=n-a></a>Proposed remedies</th></tr></thead><tbody><a name=d96685e1942 class=n-a></a><tr><a name=d96685e1944 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1946 class=n-a></a>End TB Milestones/Targets on TB<br class=br>incidence and mortality</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1951 class=n-a></a>Presented globally as percentage reductions<br class=br>compared with 2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1956 class=n-a></a>Change percentage reductions into absolute<br class=br>“national” numbers against which to measure<br class=br>progress and present them for all levels of the<br class=br>health system</td></tr><tr><a name=d96685e1966 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1968 class=n-a></a>Optimize prompt and accurate<br class=br>diagnosis of TB</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1973 class=n-a></a>Inefficient use of smear microscopy and<br class=br>Xpert MTB/RIF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1978 class=n-a></a>Develop algorithms for best use of smear<br class=br>microscopy/Xpert MTB/RIF; monitor numbers<br class=br>being screened, tests done, and results; monitor<br class=br>operational capacity of MTB/RIF instruments;<br class=br>keep abreast of new diagnostic molecular<br class=br>technology</td></tr><tr><a name=d96685e1992 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e1994 class=n-a></a>Provide rapid, complete, and<br class=br>effective treatment to all those<br class=br>diagnosed with TB</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2001 class=n-a></a>Poor linkage of diagnosis and treatment;<br class=br>wrong denominator for measuring treatment<br class=br>outcomes; high rates of “not evaluated” </td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2008 class=n-a></a>Monitor and improve linkage to care; use<br class=br>diagnosed TB patients as the denominator for<br class=br>treatment outcomes; obtain treatment outcomes<br class=br>for transfer-out patients</td></tr><tr><a name=d96685e2018 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2020 class=n-a></a>Implement and monitor<br class=br>effective infection control<br class=br>practices for <i>MTB</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2030 class=n-a></a>Poor infection control practices and<br class=br>monitoring of TB infection control</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2035 class=n-a></a>Implement and monitor World Health<br class=br>Organization-recommended guidelines; monitor<br class=br>rates of TB in health workers</td></tr><tr><a name=d96685e2043 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2045 class=n-a></a>Diagnose and treat drug-resistant TB</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2048 class=n-a></a>Poor linkage to care; continued use of<br class=br>inefficient CDST systems at national<br class=br>laboratories; long duration of therapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2055 class=n-a></a>Monitor and improve linkage to care; prioritize<br class=br>and plan for more efficient use of Xpert MTB/RIF;<br class=br>aim for short 9- to 12-month multidrug-resistant<br class=br>TB treatment; keep abreast of new diagnostic<br class=br>molecular technology</td></tr><tr><a name=d96685e2068 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2070 class=n-a></a>Diagnose and treat HIV infection and<br class=br>diabetes mellitus</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2075 class=n-a></a>HIV and diabetes increase TB mortality;<br class=br>suboptimal uptake of HIV testing, ART, and<br class=br>CPT; limited screening of TB patients for<br class=br>diabetes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2084 class=n-a></a>Aim for 100% uptake of HIV interventions; scale<br class=br>up screening of TB patients for diabetes and<br class=br>provide optimal diabetes care during anti-TB<br class=br>treatment</td></tr><tr><a name=d96685e2094 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2096 class=n-a></a>ACF and treatment of LTBI </td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2099 class=n-a></a>Poor programmatic implementation of ACF<br class=br>and treatment of LTBI </td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2104 class=n-a></a>Design and implement strategies with particular<br class=br>focus on people living with HIV and household<br class=br>contacts</td></tr><tr><a name=d96685e2112 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2114 class=n-a></a>Engage with private-for-profit sector</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2117 class=n-a></a>Poor implementation of the PPM strategy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2120 class=n-a></a>Focus on ways to improve the PPM strategy,<br class=br>especially in Asia</td></tr><tr><a name=d96685e2126 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2128 class=n-a></a>Empower and strengthen central<br class=br>units of TB Programs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2133 class=n-a></a>Weak central units </td><td align=left colspan=1 rowspan=1 valign=top><a name=d96685e2136 class=n-a></a>More focus on data-driven supportive<br class=br>supervision, operational research, and sustained<br class=br>financing</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d96685e2148 class=n-a></a><p id=d96685e2150> ACF, active case finding; ART, antiretroviral therapy; CDST, culture and drug susceptibility testing; CPT, cotrimoxazole preventive therapy; LTBI, latent tuberculosis infection; MTB, <i>Mycobacterium tuberculosis</i>; PPM, public-private mix; TB, tuberculosis.</p></div></div></div><p class="" id=d96685e2159>New paradigms also have to be embraced or else the planned new trajectories for reducing TB incidence and mortality will never be achieved. As new tools are developed, there needs to be a fast-track system for getting them pilot-tested and scaled up in the field, and this will require a broad-minded approach from national TB leadership. The clock is ticking and we need to think and act differently!</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d96685e2166>Disclaimer</h2><p class="" id=d96685e2169>The views expressed in this document are those of the authors and may not necessarily reflect those of their affiliated institutions.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d96685e1 class=n-a></a><h2 class=main-title id=d96988>Competing interests</h2><p class=metadata-entry><a name=d96685e226 class=n-a></a><p id=d96685e227> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d96685e1 class=n-a></a><h2 class=main-title id=d96990>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d96685e2176 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d97322>References</h2><div class="section ref-list"><a name=d96685e2176 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d96685e2183 class=n-a></a>United Nations: Transforming our world: the 2030 agenda for sustainable development. 2015; (accessed 10th June 2018). <a target=xrefwindow id=d96685e2185 href="https://sustainabledevelopment.un.org/content/documents/21252030%20Agenda%20for%20Sustainable%20Development%20web.pdf">Reference Source</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d96685e2194 class=n-a></a>World Health Organization: The End TB Strategy. 2015; (accessed 10th June 2018). WHO, Geneva, Switzerland. <a target=xrefwindow id=d96685e2196 href="http://www.who.int/tb/post2015_TBstrategy.pdf">Reference Source</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d96685e2205 class=n-a></a>Thwaites G: Tuberculosis: where are we going? <i>Clin Med (Lond).</i> 2006; <b>6</b>(6): 523–5. <a target=xrefwindow id=d96685e2213 href="http://www.ncbi.nlm.nih.gov/pubmed/17228547">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2216 href="http://dx.doi.org/10.7861/clinmedicine.6-6-523">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d96685e2225 class=n-a></a>World Health Organization: Global Tuberculosis Report. WHO, Geneva, Switzerland. WHO/HTM/TB/2016.13. 2016. <a target=xrefwindow id=d96685e2227 href="http://apps.who.int/iris/bitstream/handle/10665/250441/9789241565394-eng.pdf?sequence=1">Reference Source</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d96685e2236 class=n-a></a>World Health Organization: Global Tuberculosis Report. WHO, Geneva, Switzerland. WHO/HTM/TB/2017.23. 2017. <a target=xrefwindow id=d96685e2238 href="http://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf">Reference Source</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d96685e2248 class=n-a></a>Suthar AB, Zachariah R, Harries AD: Ending tuberculosis by 2030: can we do it? <i>Int J Tuberc Lung Dis.</i> 2016; <b>20</b>(9): 1148–54. <a target=xrefwindow id=d96685e2256 href="http://www.ncbi.nlm.nih.gov/pubmed/27510238">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2259 href="http://dx.doi.org/10.5588/ijtld.16.0142">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d96685e2268 class=n-a></a>Frieden TR, Brudney KF, Harries AD: Global tuberculosis: perspectives, prospects, and priorities. <i>JAMA.</i> 2014; <b>312</b>(4): 1393–4. <a target=xrefwindow id=d96685e2276 href="http://www.ncbi.nlm.nih.gov/pubmed/25188638">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2279 href="http://dx.doi.org/10.1001/jama.2014.11450">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d96685e2288 class=n-a></a>UNAIDS: 90-90-90. An ambitious treatment target to help end the AIDS epidemic. UNAIDS, Geneva, Switzerland. 2014. <a target=xrefwindow id=d96685e2290 href="http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf">Reference Source</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d96685e2299 class=n-a></a>Stop TB Partnership: The Paradigm Shift. 2016-2020. Global Plan to End TB. Geneva, Switzerland: WHO, 2016; (accessed 10th June 2018). <a target=xrefwindow id=d96685e2301 href="http://www.stoptb.org/assets/documents/global/plan/GlobalPlanToEndTB_TheParadigmShift_2016-2020_StopTBPartnership.pdf">Reference Source</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d96685e2310 class=n-a></a>Harries AD, Libamba E, Schouten EJ, <i> et al.</i>: Expanding antiretroviral therapy in Malawi: drawing on the country's experience with tuberculosis. <i>BMJ.</i> 2004; <b>329</b>(7475): 1163–6. <a target=xrefwindow id=d96685e2321 href="http://www.ncbi.nlm.nih.gov/pubmed/15539674">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2324 href="http://dx.doi.org/10.1136/bmj.329.7475.1163">Publisher Full Text </a> | <a target=xrefwindow id=d96685e2328 href="http://www.ncbi.nlm.nih.gov/pmc/articles/527699">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/5497958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2337 class=n-a></a>Boehme CC, Nabeta P, Hillemann D, <i> et al.</i>: Rapid molecular detection of tuberculosis and rifampin resistance. <i>N Engl J Med.</i> 2010; <b>363</b>(11): 1005–15. <a target=xrefwindow id=d96685e2348 href="http://www.ncbi.nlm.nih.gov/pubmed/20825313">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2351 href="http://dx.doi.org/10.1056/NEJMoa0907847">Publisher Full Text </a> | <a target=xrefwindow id=d96685e2355 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2947799">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/5497958">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d96685e2369 class=n-a></a>World Health Organization: Xpert MTB/RIF assay for diagnosis of pulmonary and extra-pulmonary TB in adults and children. Policy update. WHO/HTM/TB/2013.16. WHO, Geneva, Switzerland. 2013. <a target=xrefwindow id=d96685e2371 href="http://www.who.int/tb/publications/xpert-mtb-rif-assay-diagnosis-policy-update/en/">Reference Source</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d96685e2380 class=n-a></a>Trébucq A, Enarson DA, Chiang CY, <i> et al.</i>: Xpert<sup>®</sup> MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? <i>Int J Tuberc Lung Dis.</i> 2011; <b>15</b>(12): 1567–72. <a target=xrefwindow id=d96685e2394 href="http://www.ncbi.nlm.nih.gov/pubmed/22005110">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2398 href="http://dx.doi.org/10.5588/ijtld.11.0392">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d96685e2407 class=n-a></a>Tonganibeia A, Harries AD, Merilles OE, <i> et al.</i>: Impact of Laboratory Practice Changes on the Diagnosis of Tuberculosis with the Introduction of Xpert MTB/RIF in Kiribati. <i>Hawaii J Med Public Health.</i> 2018; <b>77</b>(2): 30–4. <a target=xrefwindow id=d96685e2418 href="http://www.ncbi.nlm.nih.gov/pubmed/29435388">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2421 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5801526">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732771131"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2430 class=n-a></a>Kweza PF, van Schalkwyk C, Abraham N, <i> et al.</i>: Estimating the magnitude of pulmonary tuberculosis patients missed by primary health care clinics in South Africa. <i>Int J Tuberc Lung Dis.</i> 2018; <b>22</b>(3): 264–72. <a target=xrefwindow id=d96685e2441 href="http://www.ncbi.nlm.nih.gov/pubmed/29471903">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2444 href="http://dx.doi.org/10.5588/ijtld.17.0491">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732771131">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733521854"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2457 class=n-a></a>Arend SM, van Soolingen D: Performance of Xpert MTB/RIF Ultra: a matter of dead or alive. <i>Lancet Infect Dis.</i> 2018; <b>18</b>(1): 8–10. <a target=xrefwindow id=d96685e2465 href="http://www.ncbi.nlm.nih.gov/pubmed/29198910">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2468 href="http://dx.doi.org/10.1016/S1473-3099(17)30695-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733521854">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d96685e2481 class=n-a></a>World Health Organization: WHO Meeting Report of a Technical Expert Consultation: Non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. WHO, Geneva, Switzerland. WHO/HTM/TB/2017.04. 2017; (accessed 10th June 2018). <a target=xrefwindow id=d96685e2483 href="http://apps.who.int/iris/bitstream/handle/10665/254792/WHO-HTM-TB-2017.04-eng.pdf?sequence=1&amp;isAllowed=y">Reference Source</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732224023"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2493 class=n-a></a>Dorman SE, Schumacher SG, Alland D, <i> et al.</i>: Xpert MTB/RIF Ultra for detection of <i>Mycobacterium tuberculosis</i> and rifampicin resistance: a prospective multicentre diagnostic accuracy study. <i>Lancet Infect Dis.</i> 2018; <b>18</b>(1): 76–84. <a target=xrefwindow id=d96685e2507 href="http://www.ncbi.nlm.nih.gov/pubmed/29198911">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2511 href="http://dx.doi.org/10.1016/S1473-3099(17)30691-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732224023">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d96685e2524 class=n-a></a>Xpert OMNI FactSheet: What to consider before Xpert Omni Implementation. (accessed 10th June 2018). <a target=xrefwindow id=d96685e2526 href="https://www.ghdonline.org/uploads/OMNI_FACTSHEET_26012018_FINAL_qyHzL8O.pdf">Reference Source</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/722945705"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2535 class=n-a></a>MacPherson P, Houben RM, Glynn JR, <i> et al.</i>: Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. <i>Bull World Health Organ.</i> 2014; <b>92</b>(2): 126–38. <a target=xrefwindow id=d96685e2546 href="http://www.ncbi.nlm.nih.gov/pubmed/24623906">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2549 href="http://dx.doi.org/10.2471/BLT.13.124800">Publisher Full Text </a> | <a target=xrefwindow id=d96685e2553 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3949536">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/722945705">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727328308"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2566 class=n-a></a>Cox H, Dickson-Hall L, Ndjeka N, <i> et al.</i>: Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study. <i>PLoS Med.</i> 2017; <b>14</b>(2): e1002238. <a target=xrefwindow id=d96685e2577 href="http://www.ncbi.nlm.nih.gov/pubmed/28222095">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2580 href="http://dx.doi.org/10.1371/journal.pmed.1002238">Publisher Full Text </a> | <a target=xrefwindow id=d96685e2584 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5319645">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727328308">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732934449"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2597 class=n-a></a>Onyoh EF, Kuaban C, Lin HH: Pre-treatment loss to follow-up of pulmonary tuberculosis patients in two regions of Cameroon. <i>Int J Tuberc Lung Dis.</i> 2018; <b>22</b>(4): 378–84. <a target=xrefwindow id=d96685e2605 href="http://www.ncbi.nlm.nih.gov/pubmed/29562984">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2608 href="http://dx.doi.org/10.5588/ijtld.17.0676">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732934449">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732905664"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2621 class=n-a></a>Htet KKK, Soe KT, Kumar AMV, <i> et al.</i>: Rifampicin-resistant tuberculosis patients in Myanmar in 2016: how many are lost on the path to treatment? <i>Int J Tuberc Lung Dis.</i> 2018; <b>22</b>(4): 385–92. <a target=xrefwindow id=d96685e2632 href="http://www.ncbi.nlm.nih.gov/pubmed/29562985">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2635 href="http://dx.doi.org/10.5588/ijtld.17.0452">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732905664">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d96685e2649 class=n-a></a>Harries AD, Salaniponi FM, Nunn PP, <i> et al.</i>: Performance-related allowances within the Malawi National Tuberculosis Control Programme. <i>Int J Tuberc Lung Dis.</i> 2005; <b>9</b>(2): 138–44. <a target=xrefwindow id=d96685e2660 href="http://www.ncbi.nlm.nih.gov/pubmed/15732731">PubMed Abstract </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d96685e2669 class=n-a></a>Afutu FK, Zachariah R, Hinderaker SG, <i> et al.</i>: High initial default in patients with smear-positive pulmonary tuberculosis at a regional hospital in Accra, Ghana. <i>Trans R Soc Trop Med Hyg.</i> 2012; <b>106</b>(8): 511–3. <a target=xrefwindow id=d96685e2680 href="http://www.ncbi.nlm.nih.gov/pubmed/22657536">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2683 href="http://dx.doi.org/10.1016/j.trstmh.2012.05.002">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d96685e2692 class=n-a></a>World Health Organization: Treatment of Tuberculosis Guidelines. Fourth Edition. WHO, Geneva, Switzerland. WHO/HTM/TB/2009.420. 2009. <a target=xrefwindow id=d96685e2694 href="http://apps.who.int/iris/bitstream/handle/10665/44165/9789241547833_eng.pdf;jsessionid=535361D9118E741D5090FECB15D7C150?sequence=1">Reference Source</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d96685e2703 class=n-a></a>World Health Organization: Treatment of Tuberculosis. Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017 update. WHO, Geneva, Switzerland. WHO/HTM/TB/2017.05. <a target=xrefwindow id=d96685e2705 href="http://www.who.int/tb/publications/2017/tb_guidelines2017_annex6_en_v4.pdf">Reference Source</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d96685e2714 class=n-a></a>World Health Organization: Definitions and reporting framework for tuberculosis – 2013 revision. WHO, Geneva, Switzerland. WHO/HTM/TB/2013.2. <a target=xrefwindow id=d96685e2716 href="http://apps.who.int/iris/bitstream/handle/10665/79199/9789241505345_eng.pdf?sequence=1">Reference Source</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d96685e2725 class=n-a></a>World Health Organization: Global Tuberculosis Report. 20th Edition. WHO, Geneva, Switzerland. WHO/HTM/TB/2015.22. 2015. <a target=xrefwindow id=d96685e2727 href="http://apps.who.int/iris/bitstream/handle/10665/191102/9789241565059_eng.pdf?sequence=1">Reference Source</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d96685e2737 class=n-a></a>Meijnen S, Weismuller MM, Claessens NJ, <i> et al.</i>: Outcome of patients with tuberculosis who transfer between reporting units in Malawi. <i>Int J Tuberc Lung Dis.</i> 2002; <b>6</b>(8): 666–71. <a target=xrefwindow id=d96685e2748 href="http://www.ncbi.nlm.nih.gov/pubmed/12150477">PubMed Abstract </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d96685e2757 class=n-a></a>Takarinda KC, Harries AD, Mutasa-Apollo T, <i> et al.</i>: Characteristics and treatment outcomes of tuberculosis patients who "transfer-in" to health facilities in Harare City, Zimbabwe: a descriptive cross-sectional study. <i>BMC Public Health.</i> 2012; <b>12</b>: 981. <a target=xrefwindow id=d96685e2768 href="http://www.ncbi.nlm.nih.gov/pubmed/23150928">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2771 href="http://dx.doi.org/10.1186/1471-2458-12-981">Publisher Full Text </a> | <a target=xrefwindow id=d96685e2775 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3585460">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d96685e2784 class=n-a></a>Bock NN, Jensen PA, Miller B, <i> et al.</i>: Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. <i>J Infect Dis.</i> 2007; <b>196 Suppl 1</b>: S108–13. <a target=xrefwindow id=d96685e2795 href="http://www.ncbi.nlm.nih.gov/pubmed/17624819">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2798 href="http://dx.doi.org/10.1086/518661">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d96685e2807 class=n-a></a>Galgalo T, Dalal S, Cain KP, <i> et al.</i>: Tuberculosis risk among staff of a large public hospital in Kenya. <i>Int J Tuberc Lung Dis.</i> 2008; <b>12</b>(8): 949–54. <a target=xrefwindow id=d96685e2818 href="http://www.ncbi.nlm.nih.gov/pubmed/18647456">PubMed Abstract </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727449350"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2827 class=n-a></a>Dheda K, Gumbo T, Maartens G, <i> et al.</i>: The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respir Med.</i> 2017; <b>5</b>(4): 291–360. pii: S2213-2600(17)30079-6. <a target=xrefwindow id=d96685e2838 href="http://www.ncbi.nlm.nih.gov/pubmed/28344011">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2841 href="http://dx.doi.org/10.1016/S2213-2600(17)30079-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727449350">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727218527"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2854 class=n-a></a>Shah NS, Auld SC, Brust JC, <i> et al.</i>: Transmission of Extensively Drug-Resistant Tuberculosis in South Africa. <i>N Engl J Med.</i> 2017; <b>376</b>(3): 243–53. <a target=xrefwindow id=d96685e2865 href="http://www.ncbi.nlm.nih.gov/pubmed/28099825">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2868 href="http://dx.doi.org/10.1056/NEJMoa1604544">Publisher Full Text </a> | <a target=xrefwindow id=d96685e2872 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5330208">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727218527">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d96685e2886 class=n-a></a>World Health Organization: WHO policy on TB infection control in health-care facilities, congregate settings and households. WHO, Geneva, Switzerland. WHO/HTM/TB/2009.419. 2009. <a target=xrefwindow id=d96685e2888 href="http://www.ncbi.nlm.nih.gov/pubmed/24432438">PubMed Abstract </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733058190"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2897 class=n-a></a>Miller AC, Livchits V, Ahmad Khan F, <i> et al.</i>: Turning off the tap: Using the FAST approach to stop the spread of drug-resistant tuberculosis in Russian Federation. <i>J Infect Dis.</i> 2018. <a target=xrefwindow id=d96685e2905 href="http://www.ncbi.nlm.nih.gov/pubmed/29659912">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2908 href="http://dx.doi.org/10.1093/infdis/jiy190">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733058190">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d96685e2921 class=n-a></a>World Health Organization: Guidelines for the programmatic management of drug-resistant tuberculosis 2011 Update. WHO, Geneva, Switzerland. WHO/HTM/TB/2011.6. <a target=xrefwindow id=d96685e2923 href="http://www.ncbi.nlm.nih.gov/pubmed/23844450">PubMed Abstract </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d96685e2932 class=n-a></a>World Health Organization: WHO treatment guidelines for drug-resistant tuberculosis, 2016 Update. WHO, Geneva, Switzerland. WHO/HTM/TB/2016.04. <a target=xrefwindow id=d96685e2934 href="http://www.ncbi.nlm.nih.gov/pubmed/27748093">PubMed Abstract </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733329344"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2943 class=n-a></a>Olayanju O, Limberis J, Esmail A, <i> et al.</i>: Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. <i>Eur Respir J.</i> 2018; <b>51</b>(5): pii: 1800544. <a target=xrefwindow id=d96685e2954 href="http://www.ncbi.nlm.nih.gov/pubmed/29700106">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2957 href="http://dx.doi.org/10.1183/13993003.00544-2018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733329344">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732825216"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e2970 class=n-a></a>Pavlenko E, Barbova A, Hovhannesyan A, <i> et al.</i>: Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey. <i>Int J Tuberc Lung Dis.</i> 2018; <b>22</b>(2): 197–205. <a target=xrefwindow id=d96685e2981 href="http://www.ncbi.nlm.nih.gov/pubmed/29506617">PubMed Abstract </a> | <a target=xrefwindow id=d96685e2984 href="http://dx.doi.org/10.5588/ijtld.17.0254">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732825216">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d96685e2998 class=n-a></a>Harries AD, Michongwe J, Nyirenda TE, <i> et al.</i>: Using a bus service for transporting sputum specimens to the Central Reference Laboratory: effect on the routine TB culture service in Malawi. <i>Int J Tuberc Lung Dis.</i> 2004; <b>8</b>(2): 204–10. <a target=xrefwindow id=d96685e3009 href="http://www.ncbi.nlm.nih.gov/pubmed/15139449">PubMed Abstract </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d96685e3018 class=n-a></a>Kilale AM, Ngowi BJ, Mfinanga GS, <i> et al.</i>: Are sputum samples of retreatment tuberculosis reaching the reference laboratories? A 9-year audit in Tanzania. <i>Public Health Action.</i> 2013; <b>3</b>(2): 156–9. <a target=xrefwindow id=d96685e3029 href="http://www.ncbi.nlm.nih.gov/pubmed/26393020">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3032 href="http://dx.doi.org/10.5588/pha.12.0103">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3036 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4463101">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d96685e3045 class=n-a></a>Chadha SS, Sharath BN, Reddy K, <i> et al.</i>: Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, India. <i>PLoS One.</i> 2011; <b>6</b>(11): e26659. <a target=xrefwindow id=d96685e3056 href="http://www.ncbi.nlm.nih.gov/pubmed/22073182">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3059 href="http://dx.doi.org/10.1371/journal.pone.0026659">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3063 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3206824">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d96685e3072 class=n-a></a>Charambira K, Ade S, Harries AD, <i> et al.</i>: Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert<sup>®</sup> MTB/RIF in Zimbabwe. <i>Public Health Action.</i> 2016; <b>6</b>(2): 122–8. <a target=xrefwindow id=d96685e3086 href="http://www.ncbi.nlm.nih.gov/pubmed/27358806">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3090 href="http://dx.doi.org/10.5588/pha.16.0005">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3093 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4913675">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d96685e3102 class=n-a></a>World Health Organization: The Shorter MDR-TB Regimen. WHO, Geneva, Switzerland. 2016; (accessed 10th June 2018). <a target=xrefwindow id=d96685e3104 href="http://www.who.int/tb/Short_MDR_regimen_factsheet.pdf">Reference Source</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/715898001"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3113 class=n-a></a>van Deun A, Maug AK, Salim MA, <i> et al.</i>: Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. <i>Am J Respir Crit Care Med.</i> 2010; <b>182</b>(5): 684–92. <a target=xrefwindow id=d96685e3124 href="http://www.ncbi.nlm.nih.gov/pubmed/20442432">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3127 href="http://dx.doi.org/10.1164/rccm.201001-0077OC">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/715898001">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732129992"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3141 class=n-a></a>Trébucq A, Schwoebel V, Kashongwe Z, <i> et al.</i>: Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. <i>Int J Tuberc Lung Dis.</i> 2018; <b>22</b>(1): 17–25. <a target=xrefwindow id=d96685e3152 href="http://www.ncbi.nlm.nih.gov/pubmed/29149917">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3155 href="http://dx.doi.org/10.5588/ijtld.17.0498">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732129992">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d96685e3168 class=n-a></a>World Health Organization: The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin Policy Update. WHO, Geneva, Switzerland. WHO/HTM/TB/2016.12. 2016. <a target=xrefwindow id=d96685e3170 href="http://apps.who.int/iris/bitstream/handle/10665/250586/9789241511261-eng.pdf?sequence=1">Reference Source</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d96685e3179 class=n-a></a>World Health Organization: The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy Guidance. WHO, Geneva, Switzerland. WHO/HTM/TB/2016.07. 2016. <a target=xrefwindow id=d96685e3181 href="http://apps.who.int/iris/bitstream/handle/10665/246131/9789241510561-eng.pdf?sequence=1">Reference Source</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731119352"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3190 class=n-a></a>Xie YL, Chakravorty S, Armstrong DT, <i> et al.</i>: Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. <i>N Engl J Med.</i> 2017; <b>377</b>(11): 1043–54. <a target=xrefwindow id=d96685e3201 href="http://www.ncbi.nlm.nih.gov/pubmed/28902596">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3204 href="http://dx.doi.org/10.1056/NEJMoa1614915">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3208 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5727572">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731119352">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727674997"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3221 class=n-a></a>van der Heijden YF, Karim F, Mufamadi G, <i> et al.</i>: Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa. <i>Int J Tuberc Lung Dis.</i> 2017; <b>21</b>(6): 670–6. <a target=xrefwindow id=d96685e3232 href="http://www.ncbi.nlm.nih.gov/pubmed/28482962">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3235 href="http://dx.doi.org/10.5588/ijtld.16.0843">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3239 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5536436">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727674997">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d96685e3252 class=n-a></a>World Health Organization: WHO treatment guidelines for isoniazid-resistant tuberculosis Supplement to the WHO Treatment Guidelines for Drug-resistant Tuberculosis. WHO, Geneva, Switzerland. WHO/CDS/TB/2018.7. 2018. <a target=xrefwindow id=d96685e3254 href="http://apps.who.int/iris/bitstream/handle/10665/260494/9789241550079-eng.pdf?sequence=1">Reference Source</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d96685e3264 class=n-a></a>Mukadi YD, Maher D, Harries A: Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. <i>AIDS.</i> 2001; <b>15</b>(2): 143–52. <a target=xrefwindow id=d96685e3272 href="http://www.ncbi.nlm.nih.gov/pubmed/11216921">PubMed Abstract </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d96685e3281 class=n-a></a>Lawn SD, Harries AD, Williams BG, <i> et al.</i>: Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? <i>Int J Tuberc Lung Dis.</i> 2011; <b>15</b>(5): 571–81. <a target=xrefwindow id=d96685e3292 href="http://www.ncbi.nlm.nih.gov/pubmed/21756508">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3295 href="http://dx.doi.org/10.5588/ijtld.10.0483">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3299 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4067901">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725461073"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3308 class=n-a></a>Suthar AB, Vitoria MA, Nagata JM, <i> et al.</i>: Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis. <i>Lancet HIV.</i> 2015; <b>2</b>(4): e137–50. <a target=xrefwindow id=d96685e3319 href="http://www.ncbi.nlm.nih.gov/pubmed/26424674">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3322 href="http://dx.doi.org/10.1016/S2352-3018(15)00005-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725461073">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d96685e3335 class=n-a></a>Howard AA, El-Sadr WM: Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned. <i>Clin Infect Dis.</i> 2010; <b>50 Suppl 3</b>: S238–44. <a target=xrefwindow id=d96685e3343 href="http://www.ncbi.nlm.nih.gov/pubmed/20397954">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3346 href="http://dx.doi.org/10.1086/651497">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d96685e3355 class=n-a></a>Stevenson CR, Critchley JA, Forouhi NG, <i> et al.</i>: Diabetes and the risk of tuberculosis: a neglected threat to public health? <i>Chronic Illn.</i> 2007; <b>3</b>(3): 228–45. <a target=xrefwindow id=d96685e3366 href="http://www.ncbi.nlm.nih.gov/pubmed/18083679">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3369 href="http://dx.doi.org/10.1177/1742395307081502">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1119816"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3378 class=n-a></a>Jeon CY, Murray MB: Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. <i>PLoS Med.</i> 2008; <b>5</b>(7): e152. <a target=xrefwindow id=d96685e3386 href="http://www.ncbi.nlm.nih.gov/pubmed/18630984">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3389 href="http://dx.doi.org/10.1371/journal.pmed.0050152">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3392 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2459204">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1119816">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d96685e3406 class=n-a></a>Lönnroth K, Roglic G, Harries AD: Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. <i>Lancet Diabetes Endocrinol.</i> 2014; <b>2</b>(9): 730–9. <a target=xrefwindow id=d96685e3414 href="http://www.ncbi.nlm.nih.gov/pubmed/25194886">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3417 href="http://dx.doi.org/10.1016/S2213-8587(14)70109-3">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d96685e3426 class=n-a></a>Baker MA, Harries AD, Jeon CY, <i> et al.</i>: The impact of diabetes on tuberculosis treatment outcomes: a systematic review. <i>BMC Med.</i> 2011; <b>9</b>(81): 81. <a target=xrefwindow id=d96685e3437 href="http://www.ncbi.nlm.nih.gov/pubmed/21722362">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3440 href="http://dx.doi.org/10.1186/1741-7015-9-81">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3444 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3155828">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727125543"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3453 class=n-a></a>Faurholt-Jepsen D, Range N, PrayGod G, <i> et al.</i>: Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania. <i>Trop Med Int Health.</i> 2013; <b>18</b>(7): 822–9. <a target=xrefwindow id=d96685e3464 href="http://www.ncbi.nlm.nih.gov/pubmed/23648145">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3467 href="http://dx.doi.org/10.1111/tmi.12120">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727125543">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/724141115"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3480 class=n-a></a>Reed GW, Choi H, Lee SY, <i> et al.</i>: Impact of diabetes and smoking on mortality in tuberculosis. <i>PLoS One.</i> 2013; <b>8</b>(2): e58044. <a target=xrefwindow id=d96685e3491 href="http://www.ncbi.nlm.nih.gov/pubmed/23469139">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3494 href="http://dx.doi.org/10.1371/journal.pone.0058044">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3498 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3585219">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/724141115">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727550787"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3511 class=n-a></a>Liu Q, Li W, Xue M, <i> et al.</i>: Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. <i>Sci Rep.</i> 2017; <b>7</b>(1): 1090. <a target=xrefwindow id=d96685e3522 href="http://www.ncbi.nlm.nih.gov/pubmed/28439071">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3525 href="http://dx.doi.org/10.1038/s41598-017-01213-5">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3529 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5430797">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727550787">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727537270"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3542 class=n-a></a>Workneh MH, Bjune GA, Yimer SA: Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. <i>PLoS One.</i> 2017; <b>12</b>(4): e0175925. <a target=xrefwindow id=d96685e3550 href="http://www.ncbi.nlm.nih.gov/pubmed/28430796">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3553 href="http://dx.doi.org/10.1371/journal.pone.0175925">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3556 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5400500">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727537270">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d96685e3570 class=n-a></a>World Health Organization and The International Union Against Tuberculosis and Lung Disease: Collaborative Framework for Care and Control of Tuberculosis and Diabetes. WHO/HTM/TB/2011.15. Geneva, Switzerland: WHO, 2011. <a target=xrefwindow id=d96685e3572 href="http://www.ncbi.nlm.nih.gov/pubmed/26290931">PubMed Abstract </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d96685e3581 class=n-a></a>Li L, Lin Y, Mi F, <i> et al.</i>: Screening of patients with tuberculosis for diabetes mellitus in China. <i>Trop Med Int Health.</i> 2012; <b>17</b>(10): 1294–301. <a target=xrefwindow id=d96685e3592 href="http://www.ncbi.nlm.nih.gov/pubmed/22830945">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3595 href="http://dx.doi.org/10.1111/j.1365-3156.2012.03068.x">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732713508"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3604 class=n-a></a>India Tuberculosis-Diabetes Study Group: Screening of patients with tuberculosis for diabetes mellitus in India. <i>Trop Med Int Health.</i> 2013; <b>18</b>(5): 636–45. <a target=xrefwindow id=d96685e3612 href="http://www.ncbi.nlm.nih.gov/pubmed/23458555">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3615 href="http://dx.doi.org/10.1111/tmi.12084">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732713508">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730480987"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3628 class=n-a></a>Lo HY, Yang SL, Lin HH, <i> et al.</i>: Does enhanced diabetes management reduce the risk and improve the outcome of tuberculosis? <i>Int J Tuberc Lung Dis.</i> 2016; <b>20</b>(3): 376–82. <a target=xrefwindow id=d96685e3639 href="http://www.ncbi.nlm.nih.gov/pubmed/27046720">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3642 href="http://dx.doi.org/10.5588/ijtld.15.0654">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730480987">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732450377"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3655 class=n-a></a>Degner NR, Wang JY, Golub JE, <i> et al.</i>: Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment. <i>Clin Infect Dis.</i> 2018; <b>66</b>(2): 198–205. <a target=xrefwindow id=d96685e3666 href="http://www.ncbi.nlm.nih.gov/pubmed/29325084">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3669 href="http://dx.doi.org/10.1093/cid/cix819">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3673 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5848303">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732450377">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d96685e3686 class=n-a></a>International Diabetes Federation: IDF Diabetes Atlas. 8th Edition, 2017; (Accessed 10th June 2018). <a target=xrefwindow id=d96685e3688 href="https://www.diabete.qc.ca/en/understand-diabetes/resources/getdocumentutile/IDF-DA-8e-EN-finalR3.pdf">Reference Source</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727821489"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3698 class=n-a></a>Ho J, Fox GJ, Marais BJ: Passive case finding for tuberculosis is not enough. <i>Int J Mycobacteriol.</i> 2016; <b>5</b>(4): 374–8. <a target=xrefwindow id=d96685e3706 href="http://www.ncbi.nlm.nih.gov/pubmed/27931676">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3709 href="http://dx.doi.org/10.1016/j.ijmyco.2016.09.023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727821489">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d96685e3722 class=n-a></a>World Health Organization: Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. WHO, Geneva, Switzerland. WHO/HTM/TB/2012.9. 2012. <a target=xrefwindow id=d96685e3724 href="http://www.ncbi.nlm.nih.gov/pubmed/24404639">PubMed Abstract </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d96685e3733 class=n-a></a>World Health Organization: Systematic Screening for Active Tuberculosis: Principles and Recommendations. WHO, Geneva, Switzerland. WHO/HTM/TB/2013.04. 2013. <a target=xrefwindow id=d96685e3735 href="http://www.ncbi.nlm.nih.gov/pubmed/25996015">PubMed Abstract </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d96685e3744 class=n-a></a>Kranzer K, Houben RM, Glynn JR, <i> et al.</i>: Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. <i>Lancet Infect Dis.</i> 2010; <b>10</b>(2): 93–102. <a target=xrefwindow id=d96685e3755 href="http://www.ncbi.nlm.nih.gov/pubmed/20113978">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3758 href="http://dx.doi.org/10.1016/S1473-3099(09)70326-3">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3762 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3136203">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d96685e3771 class=n-a></a>Baussano I, Williams BG, Nunn P, <i> et al.</i>: Tuberculosis incidence in prisons: a systematic review. <i>PLoS Med.</i> 2010; <b>7</b>(12): e1000381. <a target=xrefwindow id=d96685e3782 href="http://www.ncbi.nlm.nih.gov/pubmed/21203587">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3785 href="http://dx.doi.org/10.1371/journal.pmed.1000381">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3789 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3006353">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d96685e3798 class=n-a></a>Joshi R, Reingold AL, Menzies D, <i> et al.</i>: Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. <i>PLoS Med.</i> 2006; <b>3</b>(12): e494. <a target=xrefwindow id=d96685e3809 href="http://www.ncbi.nlm.nih.gov/pubmed/17194191">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3812 href="http://dx.doi.org/10.1371/journal.pmed.0030494">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3816 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1716189">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d96685e3826 class=n-a></a>Lin Y, Li L, Mi F, <i> et al.</i>: Screening patients with diabetes mellitus for tuberculosis in China. <i>Trop Med Int Health.</i> 2012; <b>17</b>(10): 1302–8. <a target=xrefwindow id=d96685e3837 href="http://www.ncbi.nlm.nih.gov/pubmed/22830951">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3840 href="http://dx.doi.org/10.1111/j.1365-3156.2012.03069.x">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732712927"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3849 class=n-a></a>India Diabetes Mellitus--Tuberculosis Study Group: Screening of patients with diabetes mellitus for tuberculosis in India. <i>Trop Med Int Health.</i> 2013; <b>18</b>(5): 646–54. <a target=xrefwindow id=d96685e3857 href="http://www.ncbi.nlm.nih.gov/pubmed/23448175">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3860 href="http://dx.doi.org/10.1111/tmi.12083">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732712927">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725715425"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3873 class=n-a></a>Gupta RK, Lucas SB, Fielding KL, <i> et al.</i>: Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. <i>AIDS.</i> 2015; <b>29</b>(15): 1987–2002. <a target=xrefwindow id=d96685e3884 href="http://www.ncbi.nlm.nih.gov/pubmed/26266773">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3887 href="http://dx.doi.org/10.1097/QAD.0000000000000802">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3891 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4568896">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725715425">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13437032"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3904 class=n-a></a>Lawn SD, Kerkhoff AD, Vogt M, <i> et al.</i>: Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. <i>Lancet Infect Dis.</i> 2012; <b>12</b>(3): 201–9. <a target=xrefwindow id=d96685e3915 href="http://www.ncbi.nlm.nih.gov/pubmed/22015305">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3918 href="http://dx.doi.org/10.1016/S1473-3099(11)70251-1">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3922 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3315025">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13437032">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726215273"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3935 class=n-a></a>Peter JG, Zijenah LS, Chanda D, <i> et al.</i>: Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. <i>Lancet.</i> 2016; <b>387</b>(10024): 1187–97. <a target=xrefwindow id=d96685e3946 href="http://www.ncbi.nlm.nih.gov/pubmed/26970721">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3949 href="http://dx.doi.org/10.1016/S0140-6736(15)01092-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726215273">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725722985"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e3962 class=n-a></a>Lawn SD, Kerkhoff AD, Burton R, <i> et al.</i>: Rapid microbiological screening for tuberculosis in HIV-positive patients on the first day of acute hospital admission by systematic testing of urine samples using Xpert MTB/RIF: a prospective cohort in South Africa. <i>BMC Med.</i> 2015; <b>13</b>(1): 192. <a target=xrefwindow id=d96685e3973 href="http://www.ncbi.nlm.nih.gov/pubmed/26275908">PubMed Abstract </a> | <a target=xrefwindow id=d96685e3976 href="http://dx.doi.org/10.1186/s12916-015-0432-2">Publisher Full Text </a> | <a target=xrefwindow id=d96685e3980 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4537538">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725722985">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d96685e3994 class=n-a></a>Gupta-Wright A, Corbett EL, van Oosterhout JJ, <i> et al.</i>: Urine-based screening for tuberculosis: a randomized trial in HIV-positive inpatients. Conference on Retroviruses and Opportunistic Infections, Boston, USA: Abstract Number 38LB. 2018. <a target=xrefwindow id=d96685e3999 href="http://www.croiconference.org/sessions/urine-based-screening-tuberculosis-randomized-trial-hiv-positive-inpatients">Reference Source</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717958366"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e4008 class=n-a></a>Fox GJ, Barry SE, Britton WJ, <i> et al.</i>: Contact investigation for tuberculosis: a systematic review and meta-analysis. <i>Eur Respir J.</i> 2013; <b>41</b>(1): 140–56. <a target=xrefwindow id=d96685e4019 href="http://www.ncbi.nlm.nih.gov/pubmed/22936710">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4022 href="http://dx.doi.org/10.1183/09031936.00070812">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4026 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3533588">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717958366">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732499042"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e4039 class=n-a></a>Fox GJ, Nhung NV, Sy DN, <i> et al.</i>: Household-Contact Investigation for Detection of Tuberculosis in Vietnam. <i>N Engl J Med.</i> 2018; <b>378</b>(3): 221–9. <a target=xrefwindow id=d96685e4050 href="http://www.ncbi.nlm.nih.gov/pubmed/29342390">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4053 href="http://dx.doi.org/10.1056/NEJMoa1700209">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732499042">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725523436"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e4066 class=n-a></a>Getahun H, Matteelli A, Chaisson RE, <i> et al.</i>: Latent <i>Mycobacterium tuberculosis</i> infection. <i>N Engl J Med.</i> 2015; <b>372</b>(22): 2127–35. <a target=xrefwindow id=d96685e4080 href="http://www.ncbi.nlm.nih.gov/pubmed/26017823">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4084 href="http://dx.doi.org/10.1056/NEJMra1405427">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725523436">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d96685e4097 class=n-a></a>Aït-Khaled N, Alarcon E, Bissell K, <i> et al.</i>: Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. <i>Int J Tuberc Lung Dis.</i> 2009; <b>13</b>(8): 927–35. <a target=xrefwindow id=d96685e4108 href="http://www.ncbi.nlm.nih.gov/pubmed/19723371">PubMed Abstract </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d96685e4117 class=n-a></a>World Health Organization: Latent tuberculosis infection. Updated and consolidated guidelines for programmatic management. WHO Geneva, Switzerland. WHO/CDS/TB/2018.4. 2018. <a target=xrefwindow id=d96685e4119 href="http://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf?sequence=1">Reference Source</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d96685e4129 class=n-a></a>Suthar AB, Lawn SD, del Amo J, <i> et al.</i>: Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. <i>PLoS Med.</i> 2012; <b>9</b>(7): e1001270. <a target=xrefwindow id=d96685e4140 href="http://www.ncbi.nlm.nih.gov/pubmed/22911011">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4143 href="http://dx.doi.org/10.1371/journal.pmed.1001270">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4147 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3404110">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730125463"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e4156 class=n-a></a>Haumba S, Dlamini T, Calnan M, <i> et al.</i>: Declining tuberculosis notification trend associated with strengthened TB and expanded HIV care in Swaziland. <i>Public Health Action.</i> 2015; <b>5</b>(2): 103–5. <a target=xrefwindow id=d96685e4167 href="http://www.ncbi.nlm.nih.gov/pubmed/26400378">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4170 href="http://dx.doi.org/10.5588/pha.15.0008">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4174 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4487488">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730125463">F1000 Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d96685e4187 class=n-a></a>Takarinda KC, Harries AD, Sandy C, <i> et al.</i>: Declining tuberculosis case notification rates with the scale-up of antiretroviral therapy in Zimbabwe. <i>Public Health Action.</i> 2016; <b>6</b>(3): 164–8. <a target=xrefwindow id=d96685e4198 href="http://www.ncbi.nlm.nih.gov/pubmed/27695678">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4201 href="http://dx.doi.org/10.5588/pha.16.0029">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4205 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5034781">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d96685e4214 class=n-a></a>Kanyerere H, Girma B, Mpunga J, <i> et al.</i>: Scale-up of ART in Malawi has reduced case notification rates in HIV-positive and HIV-negative tuberculosis. <i>Public Health Action.</i> 2016; <b>6</b>(4): 247–51. <a target=xrefwindow id=d96685e4225 href="http://www.ncbi.nlm.nih.gov/pubmed/28123962">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4228 href="http://dx.doi.org/10.5588/pha.16.0053">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4232 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5176049">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718391872"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e4241 class=n-a></a>Rangaka MX, Wilkinson RJ, Boulle A, <i> et al.</i>: Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. <i>Lancet.</i> 2014; <b>384</b>(9944): 682–90. <a target=xrefwindow id=d96685e4252 href="http://www.ncbi.nlm.nih.gov/pubmed/24835842">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4255 href="http://dx.doi.org/10.1016/S0140-6736(14)60162-8">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4259 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4233253">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718391872">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725658399"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e4272 class=n-a></a>TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, <i> et al.</i>: A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. <i>N Engl J Med.</i> 2015; <b>373</b>(9): 808–22. <a target=xrefwindow id=d96685e4283 href="http://www.ncbi.nlm.nih.gov/pubmed/26193126">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4286 href="http://dx.doi.org/10.1056/NEJMoa1507198">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725658399">F1000 Recommendation</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726056141"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e4300 class=n-a></a>Den Boon S, Matteelli A, Ford N, <i> et al.</i>: Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. <i>AIDS.</i> 2016; <b>30</b>(5): 797–801. <a target=xrefwindow id=d96685e4311 href="http://www.ncbi.nlm.nih.gov/pubmed/26730567">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4314 href="http://dx.doi.org/10.1097/QAD.0000000000000985">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4318 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5642844">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726056141">F1000 Recommendation</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727576013"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e4331 class=n-a></a>Wells WA, Uplekar M, Pai M: Achieving Systemic and Scalable Private Sector Engagement in Tuberculosis Care and Prevention in Asia. <i>PLoS Med.</i> 2015; <b>12</b>(6): e1001842. <a target=xrefwindow id=d96685e4339 href="http://www.ncbi.nlm.nih.gov/pubmed/26103555">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4342 href="http://dx.doi.org/10.1371/journal.pmed.1001842">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4345 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4477873">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727576013">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726907789"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e4358 class=n-a></a>Uplekar M: Public-private mix for tuberculosis care and prevention. What progress? What prospects? <i>Int J Tuberc Lung Dis.</i> 2016; <b>20</b>(11): 1424–9. <a target=xrefwindow id=d96685e4366 href="http://www.ncbi.nlm.nih.gov/pubmed/27776581">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4369 href="http://dx.doi.org/10.5588/ijtld.15.0536">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726907789">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d96685e4382 class=n-a></a>World Health Organization: Guide to develop a national action plan on public-private mix for tuberculosis prevention and care. WHO, Geneva, Switzerland. Licence: CC BY-NC-SA 3.0 IGO. 2017. <a target=xrefwindow id=d96685e4384 href="http://www.who.int/tb/publications/2017/Final_Tool_PPM_action_plan.pdf?ua=1">Reference Source</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d96685e4393 class=n-a></a>Makombe SD, Hochgesang M, Jahn A, <i> et al.</i>: Assessing the quality of data aggregated by antiretroviral treatment clinics in Malawi. <i>Bull World Health Organ.</i> 2008; <b>86</b>(4): 310–4. <a target=xrefwindow id=d96685e4404 href="http://www.ncbi.nlm.nih.gov/pubmed/18438520">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4407 href="http://dx.doi.org/10.2471/BLT.07.044685">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4411 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2647428">Free Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d96685e4420 class=n-a></a>Libamba E, Makombe S, Mhango E, <i> et al.</i>: Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi. <i>Bull World Health Organ.</i> 2006; <b>84</b>(4): 320–6. <a target=xrefwindow id=d96685e4431 href="http://www.ncbi.nlm.nih.gov/pubmed/16628306">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4434 href="http://dx.doi.org/10.2471/BLT.05.023952">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4438 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2627329">Free Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d96685e4448 class=n-a></a>Matthys F, van der Stuyft P, van Deun A: Universal tuberculosis control targets: not so smart. <i>Int J Tuberc Lung Dis.</i> 2009; <b>13</b>(8): 923–4. <a target=xrefwindow id=d96685e4456 href="http://www.ncbi.nlm.nih.gov/pubmed/19723369">PubMed Abstract </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d96685e4465 class=n-a></a>World Health Organization: TB Research. Putting research into policy and practice. The experience of the Malawi National Tuberculosis Programme. WHO, Geneva, Switzerland. WHO/CDS/CPC/TB/99.268. 1999. <a target=xrefwindow id=d96685e4467 href="http://www.who.int/tb/publications/research-practice-malawi/en/">Reference Source</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d96685e4476 class=n-a></a>Harries AD: Integration of operational research into National Tuberculosis Control Programmes. <i>Tuberculosis (Edinb).</i> 2003; <b>83</b>(1–3): 143–7. <a target=xrefwindow id=d96685e4484 href="http://www.ncbi.nlm.nih.gov/pubmed/12758204">PubMed Abstract </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d96685e4493 class=n-a></a>Hoa NB, Nhung NV, Kumar AM, <i> et al.</i>: The effects of placing an operational research fellow within the Viet Nam National Tuberculosis Programme. <i>Public Health Action.</i> 2016; <b>6</b>(4): 273–6. <a target=xrefwindow id=d96685e4504 href="http://www.ncbi.nlm.nih.gov/pubmed/28123967">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4507 href="http://dx.doi.org/10.5588/pha.16.0044">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4511 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5176054">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d96685e4520 class=n-a></a>Ade S, Affolabi D, Adjobimey M, <i> et al.</i>: Operational research within the national tuberculosis control programme in Benin. <i>BMC Res Notes.</i> 2017; <b>10</b>(1): 651. <a target=xrefwindow id=d96685e4531 href="http://www.ncbi.nlm.nih.gov/pubmed/29187248">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4534 href="http://dx.doi.org/10.1186/s13104-017-2987-9">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4538 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5708179">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727736057"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e4547 class=n-a></a>Atun R, Silva S, Knaul FM: Innovative financing instruments for global health 2002-15: a systematic analysis. <i>Lancet Glob Health.</i> 2017; <b>5</b>(7): e720–e726. <a target=xrefwindow id=d96685e4555 href="http://www.ncbi.nlm.nih.gov/pubmed/28619230">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4558 href="http://dx.doi.org/10.1016/S2214-109X(17)30198-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727736057">F1000 Recommendation</a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725466572"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d96685e4572 class=n-a></a>Laurence YV, Griffiths UK, Vassall A: Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review. <i>Pharmacoeconomics.</i> 2015; <b>33</b>(9): 939–55. <a target=xrefwindow id=d96685e4580 href="http://www.ncbi.nlm.nih.gov/pubmed/25939501">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4583 href="http://dx.doi.org/10.1007/s40273-015-0279-6">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4586 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4559093">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725466572">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d96685e4599 class=n-a></a>Cazabon D, Alsdurf H, Satyanarayana S, <i> et al.</i>: Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. <i>Int J Infect Dis.</i> 2017; <b>56</b>: 111–6. <a target=xrefwindow id=d96685e4610 href="http://www.ncbi.nlm.nih.gov/pubmed/27794468">PubMed Abstract </a> | <a target=xrefwindow id=d96685e4613 href="http://dx.doi.org/10.1016/j.ijid.2016.10.016">Publisher Full Text </a> | <a target=xrefwindow id=d96685e4617 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5346036">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 05 Jul 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1011&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1011&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> International Union Against Tuberculosis and Lung Disease, 68 Boulevard Saint Michel, 75006 Paris, France<br/> <sup>2</sup> London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK<br/> <sup>3</sup> International Union Against Tuberculosis and Lung Disease, No. 1 Xindong Road, 100600 Beijing, China<br/> <sup>4</sup> International Union Against Tuberculosis and Lung Disease, South-East Asia Regional Office, C-6 Qutub Institutional Area, 110016 New Delhi, India<br/> <sup>5</sup> AIDS &amp; TB Department, Ministry of Health and Child Care, 2nd Floor, Mukwati Building, Corner Livingstone Avenue and 5th Street, Harare, Zimbabwe<br/> <sup>6</sup> Special Programme for Research and Training in Tropical Disease (TDR), World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland<br/> <p> <div class=margin-bottom> Anthony D. Harries <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Yan Lin <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Ajay M.V. Kumar <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Srinath Satyanarayana <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Kudakwashe C. Takarinda <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Riitta A. Dlodlo <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Rony Zachariah <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Piero L. Olliaro <br/> <span>Roles: </span> Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1011/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 05 Jul 2018, 7:1011 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.14821.1">https://doi.org/10.12688/f1000research.14821.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Harries AD <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=16130 data-id=14821 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14821.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1011/v1/pdf?article_uuid=0036fea3-c1da-4768-a30f-82c39e0a0b4b" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.14821.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Harries AD, Lin Y, Kumar AMV <em>et al.</em> What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030? [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1011 (<a href="https://doi.org/10.12688/f1000research.14821.1" target=_blank>https://doi.org/10.12688/f1000research.14821.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=14821 id=mobile-track-article-signin-14821 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14821?target=/articles/7-1011"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16130 /> <input name=articleId type=hidden value=14821 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Keertan Dheda</strong>, Department of Medicine, University of Cape Town, Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, South Africa </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Edward Nardell</strong>, Department of Environmental Health, Harvard School of Public Health, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 05 Jul 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1011&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1011&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=13586-35651></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=36150-35652></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1011/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>05 Jul 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Keertan Dheda</strong>, Department of Medicine, University of Cape Town, Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, South Africa </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Edward Nardell</strong>, Department of Environmental Health, Harvard School of Public Health, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1011&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1011/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "What can National TB Control Programmes in...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1011/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1011/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1011/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Harries AD et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1011/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1011",
            templates : {
                twitter : "What can National TB Control Programmes in low- and middle-income.... Harries AD et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1011/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/14821/16130")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "16130");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "35651": 0,
                           "35652": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "080f21c1-e309-410f-8f44-938d02317555";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1011.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1011.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1011.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1011.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1011.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>